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Summary 
Membrane proteins connect the cytoplasm of a cell with its environment and are essential for all living 
organisms. Their primary role is to transduce signals and to transport solutes across the lipid bilayer. 
The importance of membrane proteins is underscored by the fact that over 50 % of the drugs on the 
market target membrane-embedded proteins. Several families of membrane transporters confer 
multidrug resistance (MDR) by actively extruding a broad range of drugs such as antibiotics or 
anticancer substances out of the bacterial or cancer cell. MDR transporters belong to five 
superfamilies, namely ATP binding cassette (ABC) transporters, major facilitator superfamily (MFS) 
transporters, multidrug and toxic-compound extrusion (MATE) transporters, small multidrug resistance 
(SMR) transporters and resistance nodulation division (RND) transporters. In the course of this PhD 
thesis we focused on structural, functional and biochemical investigations of the ABC transporter 
family and especially on the subclass of heterodimeric, prokaryotic ABC exporters. ABC exporters 
minimally consist of four domains. Two nucleotide binding domains (NBDs) dimerize upon 
sandwiching of two molecules of ATP at their interface and couple this motion to two transmembrane 
domains (TMDs), which provide alternating access to substrates.  
Membrane transporters are intrinsically flexible and rather unstable proteins and usually cannot be 
purified from natural sources due to low expression levels. For structural studies, membrane 
transporters need to be overexpressed and purified at the milligram scale as stable proteins. The goal 
of this thesis was to solve the structure of a heterodimeric ABC exporter, because of their medical 
relevance and because structural information about this subclass was not available so far. In Chapter 
2, a funnel approach is described to identify and purify transporters that are amenable to x-ray 
crystallography. Initially, crystallization attempts with LmrCD were performed, a well-characterized 
heterodimeric ABC exporter conferring resistance to daunomycin and other drugs in Lactococcus 
lactis. However, no crystals of LmrCD were obtained presumably due to its limited stability. Therefore 
the sequence of LmrCD was used to search for a set of homologues. This set was analyzed using a 
peptide disorder prediction program. Based on this analysis, thirteen transporters were cloned, 
expressed and purified in E. coli. Seven homologues were identified that were expressed at sufficient 
yields. They exhibited high protein stability in limited tryptic proteolysis, eluted as monodisperse 
proteins in the size exclusion chromatography analysis and gave first diffracting crystals.  
Chapter 3 describes the structure determination of the heterodimeric ABC exporter TM287/288 from 
Thermotoga maritima. Crystals of wild-type TM287/288 were obtained in the presence of the ATP 
analog AMP-PNP and belonged to the space group C2, containing one TM287/288 heterodimer per 
asymmetric unit. The structure was solved at 2.9 Å resolution by single-wavelength anomalous 
dispersion phasing. TM287/288 was crystallized in its inward-facing state with one AMP-PNP molecule 
bound to the degenerate catalytic site, which deviates from the consensus sequence in the same 
positions as the eukaryotic homologs CFTR and TAP1/2. In contrast to previous studies, it was found 
that the NBDs only partially separate and remain in contact through an interface involving the D-loop 
and the Walker A motif connecting the two ATP hydrolysis sites. Expression of TM287/288 in L. lactis 
∆lmrCD partially restored daunomycin resistance and transport of the MDR substrate BCECF-AM was 
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monitored by fluorescence spectroscopy. Purified TM287/288 exhibited high ATPase activities which 
were stimulated by the addition of the MDR substrate Hoechst 33342 upon reconstitution of 
TM287/288 in proteoliposomes. The structure for TM287/288 describes the first heterodimeric ABC 
exporter with nonequal ATP binding sites at a molecular level and provides unprecedented insight into 
the mechanism of this medically important category of ABC transporters.  
In Chapter 4 the structure of TM287/288 in its apo state devoid of bound nucleotides is presented. 
This structure allows for a detailed analysis of the structural changes associated with nucleotide 
binding to the degenerate ATPase site. Crystals belonged to the same space group as those used to 
solve the structure of TM287/288 with bound AMP-PNP and the structural differences were mainly 
located at the degenerate ATP binding site. These included the A-loop, which interacts through an 
aromatic residue with the adenine moiety of the bound nucleotide as well as in the Walker A motif 
which wraps around the γ-phosphate moiety. The NBDs were found to remain in molecular contact 
even in the absence of nucleotides. However, the NBD-NBD interaction mediated by the D-loop at the 
degenerate site appears weaker in the apo state than in the AMP-PNP bound state. Moreover, AMP-
PNP binding at the degenerate site is sensed by the Walker B motif and structurally communicated to 
the D-loop of the consensus site, which establishes two hydrogen bonds with the opposite NBD via a 
conserved aspartate. Removal of the nucleotide results in the disruptions of these hydrogen bonds 
and a remodeling of the highly flexible consensus site D-loop. Comparisons of the nucleotide-free and 
AMP-PNP bound structures therefore provide unprecedented insights into the molecular 
communication between the asymmetric ATP binding sites of heterodimeric ABC exporters.  
In Chapter 5 crystal structures of the isolated NBDs of TM287/288, NBD287 and NBD288, are 
presented. Numerous isolated NBDs of ABC exporters have been crystallized in the past and their 
structures provided important mechanistic insights. However, structural comparisons of NBDs 
crystallized in isolation and in the full-length context of ABC exporters are lacking. In contrast to full-
length TM287/288, the isolated NBDs did not show ATPase activity, neither alone nor in a mixture of 
NBD287 and NBD288. Dimer formation between the two NBDs was not observed even in the 
presence of MgATP based on size exclusion chromatography and analytical ultracentrifugation 
experiments. This analysis revealed that the isolated NBDs show structural flexibility in regions where 
interdomain contacts are established in the full-length transporter. In particular, the degenerate 
ATPase site appears unstructured in isolated NBD287. In addition, density for the D-loop of NBD288, 
which strongly interacts via an extensive hydrogen network with NBD287, is missing. This analysis 
also suggests that interdomain interactions which are established in the full-length transporter are 
important for the formation of the degenerate ATP binding site. 
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Zusammenfassung 
Membranproteine stellen eine Verbindung zwischen dem Zytoplasma einer Zelle und seiner 
Umgebung her, daher sind sie lebensnotwendig. Substanzen zu transportieren und Signale über die 
Zellmembran zu übertragen gehören zu ihren Hauptaufgaben. Ihre Wichtigkeit wird dadurch 
unterstrichen, dass über 50 % aller Medikamente auf dem Markt an Membranproteine binden. 
Mehrere Familien von Membranproteinen verleihen durch aktives Herauspumpen einer breiten Anzahl 
von Medikamenten, wie Antibiotika oder Krebsmedikamenten, aus Bakterien- oder Krebszellen 
sogenannte multispezifische Resistenz (MDR). MDR Transporter gehören einer von fünf 
Superfamilien an, den „ATP binding cassette“ (ABC) Transportern, den „major facilitator superfamily“ 
(MFS) Transportern, den „multidrug and toxic-compound extrusion“ (MATE) Transportern, den „small 
multidrug resistance“ (SMR) Transportern oder den „resistance nodulation division“ (RND) 
Transportern. Im Rahmen dieser Doktorarbeit beschränkte ich mich auf die strukturelle, funktionelle 
und biochemische Untersuchung der ABC Transporter Familie und im Speziellen der heterodimeren, 
prokaryotischen ABC Exporter. ABC Exporter sind aus mindestens vier Domänen aufgebaut. Die 
Bindung von zwei ATP Molekülen am „interface“ der Nukleotid-Bindedomänen (NBDs) führt zu deren 
Dimerisierung. Diese Bewegung wird an die Transmembrandomänen weitergeleitet, welche 
alternierenden Zugang von Substraten innerhalb oder ausserhalb der Zelle gewährleisten. 
Membrantransporter sind intrinsisch flexible und unstabile Proteine und können wegen niedrigen 
Expressionsraten selten aus natürlichen Quellen aufgereinigt werden. Für strukturelle Untersuchungen 
müssen Membrantransporter daher rekombinant (z.B. in Escherichia coli) im Milligrammmassstab 
hergestellt und gereinigt werden. Das Ziel dieser Doktorarbeit war die Strukturaufklärung eines 
heterodimeren ABC Exporters. Dies einerseits, weil bis anhin keine Struktur eines solchen gelöst 
wurde und anderseits wegen deren hoher medizinischer Relevanz. In Kapitel 2 wird das Vorgehen 
beschrieben, wie ein geeigneter Transporter für die Strukturanalyse identifiziert wurde. Der Startpunkt 
für die Kristallisationsbemühungen war LmrCD, ein gut untersuchter heterodimerer ABC Exporter, 
welcher Lactococcus lactis Resistenz gegen Daunomycin und andere Antibiotika verleiht. Leider 
konnte LmrCD nicht kristallisiert werden, dies möglicherweise wegen dessen limitierter Stabilität. 
Daher wurde die Aminosäuresequenz von LmrCD verwendet, um homologe Proteine zu suchen, 
welche mit Hilfe eines Peptid-Stabilität Programms zusätzlich analysiert wurden. Basierend auf dieser 
Analyse wurden dreizehn Transporter kloniert, in E. coli exprimiert und gereinigt. Sieben Homologe 
konnten so identifiziert werden, die in genügender Menge exprimiert wurden, eine hohe Stabilität 
gegenüber limitiertem tryptischem Verdau aufwiesen, als monodisperse Proteine von der analytischen 
Gelfiltration eluierten und erste diffraktierende Kristalle ergaben.  
Kapitel 3 beschreibt die Strukturaufklärung des heterodimeren ABC Exporters TM287/288 aus 
Thermotoga maritima. Kristalle von Wildtyp TM287/288 konnten in der Anwesenheit von AMP-PNP, 
einem ATP Analog, erhalten werden. Die Kristalle gehörten der Raumgruppe C2 an, mit einem 
TM287/288 Heterodimer pro asymmetrischer Einheit. Die Struktur konnte mit Hilfe von „single-
wavelength anomalous dispersion“ Phasierung bei einer Auflösung von 2.9 Å gelöst werden. 
TM287/288 wurde in der „inward-facing“ Konformation mit nur einem an die degenerierte ATP-
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Bindungsstelle gebundenen AMP-PNP Molekül kristallisiert. Diese degenerierte katalytische 
Bindungsstelle weicht in den gleichen Positionen der Aminosäuresequenz von der Konsensussequenz 
ab, wie auch die eukaryotischen Homologe CFTR und Tap1/2. Im Gegensatz zu früheren Studien 
konnten wir beobachten, dass sich die NBDs nur teilweise trennen und durch eine starke Interaktion 
zwischen dem D-loop und dem Walker A zusammengehalten werden. Expression von TM287/288 in 
L. lactis ∆lmrCD führte zu partieller Resistenz gegen Daunomycin. Des Weiteren konnte der Transport 
des MDR Substrates BCECF-AM mit Hilfe von Fluoreszenz Spektroskopie in TM287/288 
überexprimierenden L. lactis ∆lmrCD Zellen nachgewiesen werden. Der gereinigte Transporter 
TM287/288 wies eine hohe ATPase Aktivität auf. Diese wurde zusätzlich durch das MDR Substrat 
Hoechst 33342 stimuliert, wenn der Transporter vorher in Proteoliposomen rekonstituiert wurde. Die 
Struktur von TM287/288 ist die erste Struktur eines heterodimeren ABC Exporters, welcher 
nichtidentische ATP Bindungsstellen aufweist. Sie erlaubt neue Einblicke in den Mechanismus dieser 
medizinisch wichtigen Klasse von ABC Transportern.  
In Kapitel 4 wird die apo Struktur von TM287/288 beschrieben. Durch die Struktur werden detaillierte 
Aussagen über die strukturellen Veränderungen durch Nukleotid Bindung an die degenerierte ATP 
Bindungsstelle ermöglicht. Die Kristalle gehörten derselben Raumgruppe an, wie diejenigen die zur 
AMP-PNP Struktur geführt hatten. Die strukturellen Unterschiede beschränken sich hauptsächlich auf 
die degenerierte Bindungsstelle. Diese schliessen Veränderungen im A-loop ein, welcher durch eine 
aromatische Aminosäure mit dem Adeninring des gebundenen Nukleotids interagiert. Des Weiteren 
sieht man Veränderungen im Walker A Motiv, welches sich um das γ-Phosphat des Nukleotids windet. 
Die beiden NBDs bleiben sogar in Abwesenheit eines ATP Moleküls in molekularem Kontakt 
miteinander, wobei die durch den D-loop vermittelte NBD-NBD Interaktion an der degenerierte 
Bindungsstelle in Abwesenheit eines Nukleotids schwächer wird. AMP-PNP Bindung an die 
degenerierte Bindungsstelle wird durch das Walker B Motiv wahrgenommen und an den D-loop der 
konservierten aktiven Bindungsstelle weitergeleitet. Daraufhin werden zwei Wasserstoffbrücken mit 
dem gegenüberliegenden NBD durch ein konserviertes Aspartat (D-loop) ausgebildet. Die Entfernung 
des Nukleotids zerstört die zwei Wasserstoffbrücken und führt zu starken konformationellen 
Veränderungen im höchst flexiblen D-loop der konservierten Bindungsstelle. Der Vergleich der beiden 
gelösten TM287/288 Strukturen (AMP-PNP/apo) erlaubt somit neue Einblicke in die molekulare 
Kommunikation zwischen den beiden asymmetrischen ATP Bindungsstellen bei heterodimeren ABC 
Exportern.  
In Kapitel 5 werden die Kristallstrukturen der isolierten NBDs NBD287 und NBD288 von Volllängen-
TM287/288 präsentiert. Eine Vielzahl von isolierten NBDs von ABC Exportern wurden in der 
Vergangenheit gelöst, welche wichtige mechanistische Einblicke erlaubten. Was aber fehlte ist der 
Vergleich von isolierten NBDs mit NBDs im Kontext ein- und desselben intakten ABC Exporters. 
NBD287 und NBD288 zeigten weder alleine noch als 1:1 Mischung messbare ATPase Aktivität, ganz 
im Gegensatz zum intakten Transporter. Dimerbildung in Anwesenheit von MgATP konnte weder in 
Gelfiltrations- noch in analytischen Ultrazentrifugationsexperimenten beobachtet werden. Unsere 
Analysen der isolierten NBDs ergaben, dass sie hohe strukturelle Flexibilität in Regionen aufweisen, 
die in Interdomänen Kontakten im intakten Transporter involviert sind. Im Besonderen scheint die 
degenerierte ATP Bindungsstelle im isolierten NBD287 unstrukturiert zu sein. Zusätzlich, war keine 
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Elektronendichte für den D-loop von NBD288 sichtbar, welcher im Volllängenprotein mittels eines 
starken Wasserstoffbrücken Netzwerks mit NBD287 interagiert. Die Interaktion zwischen den 
Domänen, wie man sie im Volllängentransporter sieht, ist daher Voraussetzung für die Ausbildung der 
degenerierten Bindungsstelle.
 1  
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1 Introduction 
1.1 Discovery of Microorganisms 
In the late 17th century Robert Hooke and Antoni van Leeuwenhoek were amongst the first describing 
bacteria and other microorganisms using primitive single-lens microscopes. In the 19th century the 
German botanist Ferdinand Cohn founded the field of bacteriology by proposing amongst others a 
way to classify bacteria. Contemporaneously, the French chemist Louis Pasteur together with the 
German physician Robert Koch created the field of microbiology or more precisely the field of medical 
microbiology. These foundations were possible due to the development of oil-immersion microscopes 
with a higher resolution. Louis Pasteur is best known for his success in food preservation and was in 
addition significantly involved in the disproval of the theory of “spontaneous generation” developed by 
Aristotle about 400 B.C., describing the generation of living material from non-living material. Pasteur 
could show in experiments with swan-necked flacks (Pasteur flasks) that spontaneous generation 
does not exist but that the growth of microorganisms in sterilized nutrient solutions can be ascribed to 
air-born microbes. Pasteur also developed vaccines for the diseases anthrax and rabies. Robert Koch 
became famous for the so-called Koch’s postulates about the “germ theory of diseases”. He showed 
the direct connection between disease (effect) and the occurrence of pathogenic microorganisms 
(cause). This was possible by the isolation of a pathogen from a diseased animal and its subsequent 
growth in pure liquid culture or on agar plates. Reinjection into a healthy animal aroused the disease 
again. The work with pure cultures led to the discovery of several pathogenic bacterial strains, e.g. 
Mycobacterium tuberculosis[1]. 
1.2 Development of Antibiotics 
The groundbreaking findings of Robert Koch that the causative agents of so-called infectious diseases 
are microorganisms and the observation of Louis Pasteur that some bacteria show an antagonism 
between each other strongly stimulated the search for antibacterials. Koch and Pasteur described a 
phenomenon called antibiosis, where the growth of Bacillus anthracis cultures was inhibited by 
another airborne Bacillus species. Antagonistic effects of fungi against bacteria were also described by 
John Tyndall. In 1928 Alexander Fleming observed a similar effect that a fungus from the genus 
Penicillium exhibited against certain bacteria. Fleming assigned this effect to a compound he named 
penicillin. In 1932, the first sulphonamide called Prontosil, from Bayer Laboratories became 
commercially available. Thereafter, the progress in development of antibacterial agents was stimulated 
dramatically. In 1939, Gramicidin from B. brevis was discovered, which was used to treat wounds 
during World War II. Ernst Chain and Howard Florey purified penicillin G procaine in 1942. For their 
work they received the Nobel Prize in Medicine 1945 together with Alexander Fleming[1]. The 
discovery of penicillin tremendously stimulated the research in the field of antibiotic development and 
discovery. Many more antibiotics were developed until the end of the 1960s and became commercially 
available. After the 1960s the progress in the development of antibiotics was slowed down severely 
because the majority of the infectious diseases were believed to be conquered. 
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1.3 Mechanisms of Antibiotic Action 
The antibiotic susceptibility of different microorganisms is variable and depends on several factors. 
Gram-positive bacteria and Gram-negative bacteria for example often show a different susceptibility 
towards an individual antibiotic. Broad-spectrum antibiotics are often effective against both groups. 
The dose of an antibiotic and the exposure time to it is an additional, very important factor.  
Figure 1 summarizes the main mechanisms of antibiotic action and the place of intervention. These 
mechanisms can be classified in three main groups: nucleic acid synthesis, protein synthesis and cell 
wall synthesis. These classes can be further subdivided. Certain antibiotics or groups of antibiotics for 
example precisely target the individual subunits of the prokaryotic ribosome, either 30S or 50S and 
influence in this way protein synthesis. Other antibiotics interfere with nucleic acid synthesis by 
blocking the DNA gyrase or by inhibiting the DNA dependent RNA polymerase. A third mechanism to 
impede with DNA synthesis is the folate synthesis pathway. Folate is a DNA precursor and therefore 
blockage of its synthesis pathway is lethal for an organism. 
 
FIGURE 1| Points of action of antibiotics within a bacterial cell[2]. 
1.4 Antibiotic Resistance 
Antibiotic resistance is a common, natural and ancient phenomenon [3, 4]. In the year 1952 Esther 
and Joshua Lederberg conducted first experiments showing that penicillin resistant strains existed 
before penicillin treatment and Joshua Lederberg in addition could show the occurrence of resistant 
strains against streptomycin. Genes transferring antibiotic resistance are collected in the so-called 
resistome[5]. But in general the occurrence of natural antibiotic-resistant strains is not the reason for 
the present-day’s situation. It’s the today’s misuse and overuse of antibiotics in human and veterinary 
medicine and in agriculture that increased the evolutionary pressure on bacterial strains to form 
resistance phenotypes. Flu and colds, which are caused by viruses, are frequently treated with 
antibiotics, which do not have any biological influence on their life cycle. This practice seems to be so 
prevalent that the Food and Drug Administration (FDA) has to run dedicated information programs 
(Figure 2). The exposure time of a pathogen to a drug and the prescribed dose are as well of high 
importance. A low dose or a short exposure time for example does not kill all bacteria, but instead puts 
a selection pressure on the microorganism, allowing spontaneous drug target mutations. In addition, 
antibiotics were and still are deployed in certain countries in livestock breeding as growth promoters 
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for cattle, pigs and chickens[6]. The use of antibiotics as growth enhancer in fish farms is as well in 
common use. Development of antibiotic resistance simply follows the law of natural selection 
described by Charles Darwin, which means the adaptation to a changed, tightened environment with 
subsequent survival advantage. Figure 3 shows bacterial cells forming colonies plated on two agar 
plates containing paper discs soaked with antibiotics. The cells on the left plate are much more 
susceptible to the tested antibiotics than the cells grown on the right plate with the same antibiotics. 
This is because the cells on the right plate built up a resistance against the antibiotics. 
 
FIGURE 2| Food and Drug Administration (FDA) warning[7]. 
 
 
FIGURE 3| Antibiotic susceptibility, disc growth assays[8]. 
 
Resistance phenotypes can evolve by spontaneous or induced genetic mutations or by the acquisition 
of genes in a process called horizontal gene transfer[9]. This transfer is often facilitated by the fact that 
these resistance genes are encoded on plasmids, which allow a simplified transfer via conjugation, 
transformation or transduction. In the lower panel of Figure 4 the appearance of first phenotypes of 
resistance against a developed antibiotic are shown. It is frightening how fast such an adaptation to a 
certain antibiotic can proceed. Therefore, infectious diseases are today again a world leading cause of 
death and forgotten infection diseases experience a renaissance[10]. 
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FIGURE 4| Development of antibiotics and appearance of first resistant bacterial strains[11]. 
1.5 Molecular Resistance Mechanisms 
Horizontal gene transfer is in many cases the reason for the acquisition of antibiotic resistance. The 
presence of an antibiotic against pathogens puts them under selection pressure. Pathogens with a 
genetic alteration in an affected antibiotic-targeted protein then receive a survival or growth 
advantage. Four principal resistance mechanisms that are employed by microorganisms are 
distinguished (Figure 5). 1. Drug modification or inactivation. Drugs can be chemically modified and 
thereby become inactive. Penicillin resistant strains produce β-lactamases (e.g. penicillinase) that 
enzymatically hydrolyse the β-lactam ring[12]. To overcome this problem, penicillinase stable 
antibiotics like methicillin were developed. But this success did not last for long, because as seen in 
Figure 4 resistance against the penicillinase stable methicillin appeared very rapidly. 2. Target 
modification. The target of penicillins, the penicillin binding protein (PBP) can be modified by mutations 
lowering the affinity of the antibiotic to PBP[12]. Other examples are modifications of the gyrase or the 
methylation of the ribosome, for example in the ribosomal RNA[13], which inhibits the interaction with 
the antibiotic. 3. Changes in metabolic pathways. Sulfonamide resistant bacteria no longer require p-
aminobenzoic acid (PABA), the precursor for the synthesis of folic and the subsequent nucleic acids. 
Folic acid synthesis is blocked by sulfonamides[14]. 4. Lowered drug accumulation. In many bacteria, 
membrane permeability for antibiotics or other antibacterial agents decreases. This is achieved by 
down-regulation of the expression of outer-membrane proteins called porins[15] or increased 
expression of polyspecific efflux pumps or multidrug transporters (MDR) with a wide range of 
specificity to extrude noxious substances from the cells. 
 
Figure 5| Resistance mechanisms[16] 
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1.6 Efflux Pumps and (MDR) Transporters 
Multidrug transporters belong to five superfamilies[17], the ATP binding cassette (ABC) family, the 
major facilitator superfamily (MFS), the multidrug and toxic-compound extrusion (MATE) family, the 
small multidrug resistance (SMR) family and the resistance nodulation division (RND) family. Next to 
primary active ABC transporters, using the energy of ATP binding and hydrolysis, the MDR family 
contains another four secondary active transporters (MSF, MATE, SMR, and RND). They use the 
energy that is stored in the proton (H+) or the sodium (Na+) gradient across cellular membranes. 
Transporters of the MATE (e.g. NorM from Erwinia amylovora) and SMR (e.g. QacC from 
Staphylococcus aureus) family only exist in Gram-positive bacteria. ABC transporters are found in 
Gram-positive (e.g. LmrA from L. lactis) and in Gram-negative bacteria (e.g. MacB from Escherichia 
coli). MFS are as well found in both Gram species, e.g. QacA (S. aureus) and EmrB (E. coli). RNDs 
(e.g. AcrB from E. coli) are mainly present in Gram-negative bacteria. MDR transporters from Gram-
negative bacteria (e.g. AcrB, MacB and EmrB, examples are given for E. coli) are part of tripartite 
efflux systems, containing an additional membrane fusion protein (AcrA, MacA and EmrA), which 
connects the transporter to the outer membrane protein TolC[18]. Figure 6 shows the described 
transporters in an overview.  
Functional, biochemical and especially structural data for these MDR transporters help to understand 
the mechanism of drug transport mediated by these medically important proteins. Obtaining structural 
data for membrane proteins is a difficult task. Nevertheless, structures of all five classes described 
above could be solved by x-ray crystallography. The structure of the first member was solved in 2002 
by Murakami et al., namely the structure of the homotrimeric RND transporter AcrB crystallized in a 
symmetric form[19]. In 2006 and 2007, three further structures of AcrB were described, all crystallized 
in an asymmetric form[20-22]. Two additional RND structures were solved thereafter, the structure of 
MexB from Pseudomonas aeruginosa and the heavy-metal efflux transporter CusA[23, 24]. CusA was 
crystallized as well together with its membrane fusion protein CusB[25]. Finally, in 2011 and 2012 
researchers were able to solve AcrB structures with the bound substrates rifampicin, erythromycin, 
minocycline and doxorubicin, giving the first insight into drug binding and possible sites for efflux pump 
inhibition[26, 27]. With the three structures of homodimeric Sav1866 (ABC), homodimeric MsbA (ABC) 
and monomeric EmrD (MFS) all published in 2006 two additional structures of members of the MDR 
family were made accessible[28-30]. EmrD was shown to be very similar to the MFS transporters 
LacY, a lactose permease and GlpT, a glycerol-3-phosphate transporter described before[31, 32]. In 
2009 the structure of mouse P-glycoprotein (P-gp), a transporter shown to be involved in drug 
resistance in cancer cells, was solved and binding of two artificial, cyclic substances was 
described[33]. Another P-gp structure of C. elegans was published in 2012. In 2007, the structure of 
the homodimeric SMR transporter EmrE was added to the quintet[34]. And finally in 2010 the structure 
of monomeric NorM from Vibrio cholerae belonging to the MATE superfamily was solved, thereby 
completing the gallery of MDR transporters[35]. Recently, two further structures of NorM from 
Neisseria gonorrheae and of a MATE from Pyrococcus furiosus (PfMATE) were solved with bound 
drugs[36, 37]. Even though the number of transporter structures has increased in the past years, the 
amount of data is unfortunately still not sufficient to propose a substantiated mechanism for all the 
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different MDR transporters. Not for all transporter families structures with bound substrates are 
available. Moreover crystal structures describing the various states and conformations of the transport 
cycle are missing and efforts to combine structural and functional experiments are limited. Further 
studies are therefore needed to understand how multidrug transporters function to reach the long-term 
goal to specifically target or inhibit MDR efflux. 
 
FIGURE 6| Multidrug-resistance efflux pumps, adapted from[38]. 
 
 
Figure 7| Side by side x-ray structure comparison of the five existing MDR transporter families 
ATP
ADP + Pi
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1.7 ABC Exporters 
One major cause of antibiotic resistance is the increased pumping activity of microbial ABC exporters, 
which diminishes the effective drug concentration inside the microbial cell. The same holds true for 
eukaryotic ABC transporters, which were found to be connected to multidrug resistance (MDR) in 
cancer cells by extruding broad ranges of anticancer agents.  
As for all transporters, it is generally accepted that ABC transporters work according to the alternating 
access mechanism[39]. In the inward-facing state, ABC exporters bind their cargo in a large cavity 
formed by the transmembrane domains (TMDs)[33]. After binding of ATP at the nucleotide binding 
domains (NBDs), leading to their dimerization in a head to tail manner, the transporter adopts an 
outward-facing conformation involving major conformational changes in the TMDs and the cargo can 
be released[28]. The conformational rearrangements in the NBDs are transmitted via the so-called 
coupling helices to the TMDs. The ATP-driven dimerization upon ATP binding at the NBDs has been 
proposed as the power stroke of ABC transporters[40]. After hydrolysis of ATP, ADP and inorganic 
phosphate is released, the NBDs separate and the transporter returns back into an inward-facing 
state. ABC exporters exist in homodimeric and heterodimeric forms, bearing either two or only one 
consensus ATPase site per transporter, respectively. Many medically important eukaryotic ABC 
transporters are heterodimers; examples are the transporter associated with antigen processing 
(Tap1/2)[41], the cystic fibrosis transmembrane regulator (CFTR)[42], the sulfonylurea receptor 1 
(SUR1)[43] and the multidrug resistance-associated protein 1 (MRP1)[44]. Bacterial heterodimeric 
ABC transporters such as LmrCD and PatAB have been shown to be responsible for resistance 
against several antibacterial agents. Whereas the amino acid sequences of the TMDs of ABC 
transporters are variable, the NBDs contain highly conserved sequence motifs (Chapter 4, Figure 1).  
The A-loop motif contains an aromatic amino acid (Tyr, Phe or Trp) and is involved in nucleotide 
binding by making pi-stacking interactions with the adenine moiety of ATP. It is positioned about 25 
residues upstream of the Walker A motif[45]. The Walker A (consensus: GxxGxGK) itself, contains a 
well conserved lysine residue and is involved in ATP binding. The lysine side chain orients the β- and 
the γ-phosphate of the ATP and is therefore as well involved in nucleotide hydrolysis[46]. Another 
common motif of many ATPases, the Walker B motif (consensus: ΦΦΦΦDE; Φ = aliphatic amino acid) 
is critical for ATP hydrolysis. The Walker B glutamate plays the role of the catalytic base, and is 
responsible for the orientation and polarisation of a water molecule, which is itself attacking and 
hydrolysing the γ-phosphate of the nucleotide[47]. The ABC signature motif (consensus: LSGGQ), 
which interacts in a head-to-tail manner with the Walker A motif of the other NBD is involved in ATP 
binding by sandwiching it in between[48]. The other motif involved in ATP hydrolysis is the H- (switch-) 
loop, which has a consensus histidine that functions as the general acid[48]. The Walker B glutamate 
and the H-loop histidine together build a catalytic dyad[47]. The Q-loop, a conserved glutamine is 
believed to be involved in nucleotide sensing and in addition in interdomain communication. Last but 
not least the D-loop (consensus: SALD) plays a role in inter-NBD communication as proposed based 
on isolated NBD structures[47].  
In heterodimeric ABC transporters some of these conserved motifs deviate from the consensus 
sequence. In the prokaryotic heterodimeric ABC transporter LmrCD for example the Walker B 
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sequence is ΦΦΦΦDD in LmrC deviating from consensus ΦΦΦΦDE in LmrD. The sequence of the D-
loop is changed from SALD to SNVD and the switch histidine is changed to a glutamine[49]. In 
addition, the sequence of the ABC signature motif is changed from FSGGQ to FSVGQ. Therefore 
these ATPase sites are called the degenerate ATPase sites.  
In the last ten years progress has been made in solving crystal structures of full-length ABC 
transporters. For the exporter subtype there are four bacterial and three eukaryotic structures available 
(all heterodimeric, ABCB10 counted as one). In Sav1866, a protein from the bacteria S. aureus solved 
at a resolution of 3 Å, the NBDs are dimerized and show an outward-facing conformation with two 
nucleotides (either ADP or AMP-PNP) tightly bound at the NBDs[28]. MsbA from E. coli, V. cholerae 
and S. typhimurium were crystallized in three different conformations. In the 3.7 Å structure of the S. 
typhimurium protein, binding of two AMP-PNP or ADP·Vi can be observed and it shows an outward-
facing conformation, very similar to that of Sav1866. In the 5.3 Å E. coli and the 5.5 Å V. cholerae 
structures no nucleotides are bound and the proteins show inward-facing conformations[30] with the 
nucleotide binding domains (NBDs) separated by 68.46 Å and 32.75 Å, respectively (Chapter 4, Figure 
9). The first eukaryotic ABC transporter structure of mouse P-gp solved at 3.8 Å resolution depicts an 
inward-facing conformation, with no nucleotides bound[33]. The second eukaryotic structures of 
ABCB10 from human mitochondria solved at 3.3 Å, 2.9 Å and 2.85 Å again show inward-facing 
conformations, but binding of two AMP-PNP or two AMP-PCP molecules could be observed. Two 
more ABCB10 structures are available in nucleotide-free form[50]. The third, most recent eukaryotic 
structure is a structure of nucleotide-free C. elegans P-gp solved to a resolution of 3.4 Å[51]. A gallery 
of these ABC transporter structures is shown in Figure 9, Chapter 4. At the time when this PhD thesis 
was started in 2009, no structure was available for a heterodimeric transporter neither eukaryotic nor 
prokaryotic, despite the fact that they are of high medical relevance and include the proteins CFTR, 
MRP1 or Tap1/2[41, 42, 44]. 
1.8 Aim of Thesis 
ABC exporters have been shown to be involved in multidrug resistance (MDR) in prokaryotes as well 
as in eukaryotes. Examples for eukaryotic multidrug ABC transporters are P-gp and MRP1, which both 
confer resistance against anticancer drugs in tumor cells. Furthermore, mutations in the heterodimeric 
ABC transporters CFTR and SUR1 are responsible for the hereditary diseases cystic fibrosis, 
congenital hyperinsulinism and for susceptibility to type 2 diabetes. Heterodimeric, prokaryotic ABC 
exporters like LmrCD or PatAB confer drug resistance against antibiotics in L. lactis and Streptococcus 
pneumoniae. At the onset of this project in 2009, structural data was unavailable for prokaryotic and 
eukaryotic members of the subclass of heterodimeric ABC exporters. Little was known about potential 
differences or similarities between the ATP binding and the hydrolysis mechanism of homodimeric or 
heterodimeric ABC exporters.  
The aim of this thesis was to obtain deeper insights into the transport and hydrolysis mechanism of 
ABC exporters in general and more precisely into the subclass of heterodimeric ABC exporters. To 
this end, x-ray crystallography was combined with biochemical and microbiological analyses. In a first 
step, prokaryotic homologues of the heterodimeric ABC exporter LmrCD from Lactococcus lactis were 
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probed for their stability and crystallizability (Chapter 2). Subsequently, the structure of the first 
heterodimeric ABC exporter, TM287/288 from Thermotoga maritima, was solved with one bound AMP-
PNP and its function was analyzed in vitro as well as in vivo (Chapter 3). TM287/288 was as well 
crystallized in the absence of nucleotides, which revealed novel insights into the molecular 
communication between the asymmetric catalytic sites of heterodimeric ABC exporters (Chapter 4). 
Finally, the isolated NBDs of TM287/288 were crystallized to understand the importance of 
interdomain contacts between the NBDs themselves and the coupling between the NBDs and the 
TMDs in the context of the full-length transporter (Chapter 5).  
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2.1 Introduction 
Membrane proteins constitute a class of very important molecules. About 20-30 % of the genes in a 
genome encode for these lipophilic proteins(1). The importance is underlined by the fact that more 
than 50 % of the current medical drugs target membrane embedded proteins(2). Membrane proteins 
facilitate the exchange of signals and substances between the extracellular and the intracellular 
environment. Transport proteins have a wide spectrum of substrates that ranges from trace elements 
to vitamins to even entire proteins. The transport of a cargo has often directionality, meaning that it 
can either be imported into or exported out of a cell(3). In addition, the field discriminates between a 
direct (primary active, using ATP) and an indirect (secondary active, exploiting the electrochemical 
gradient) energy coupling. It has been shown that some membrane transporters are involved in 
multidrug resistance (MDR)(4). MDR describes the ability of microorganisms or cancer cells to extrude 
noxious substances, such as antibiotics or anticancer drugs, out of the cell by hijacking existing 
transport systems, which originally evolved to transport physiological substrates.  
Despite the importance of membrane proteins and the progress that has been made in handling these 
labile, flexible and often poorly expressed molecules, less than 0.1 % of the deposited structures in the 
protein data bank (PDB) originate from membrane embedded proteins 
(http://blanco.biomol.uci.edu/mpstruc/listAll/list).  
The superfamily of ATP binding cassette (ABC) transporters belongs to the class of primary active 
transport proteins. They are found in all kingdoms of life(5). ABC transporters exist as substrate 
binding protein (SBP) dependent importers in prokaryotes, and as exporters in all organisms. In 
eukaryotes, the ABC exporters P-glycoprotein, MRP1 and ABCG2 were connected to resistance 
against anticancer agents(6, 7). The two prokaryotic ABC exporters PatAB from Streptococcus 
pneumoniae and LmrCD from Lactococcus lactis have been shown to extrude a large variety of drugs 
out of the cell(8, 9). PatAB and LmrCD belong to the subclass of prokaryotic, heterodimeric ABC 
exporters(10). The structure of the recently solved TM287/288, a heterodimeric ABC transporter from 
the thermophilic bacterium Thermotoga maritima, sheds for the first time light on the structure of this 
subclass(11). TM287/288 serves as a structural model for LmrCD, PatAB and other medically relevant 
eukaryotic, heterodimeric ABC exporters such as CFTR, MRP1, SUR1 and Tap1/2 (7, 12-14).  
The aim of this thesis was to crystallize a heterodimeric ABC exporter. In this chapter we present a 
funnel approach(15) to select for stable homologues of this subclass with favorable biophysical and 
biochemical properties for functional and structural studies. This attempt resulted in two different x-ray 
structures of the heterodimeric ABC transporter TM287/288 from T. maritima(11) (Chapter 3 and 
Chapter 4). In addition, we were able to express and additionally crystallize some of the other selected 
homologues. All crystals were tested for their diffraction quality and for some full data sets were 
collected. 
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2.2 Material and Methods 
2.2.1 Blastp 
The amino acid sequence of LmrC of the heterodimeric ABC transporter LmrCD from Lactococcus 
lactis subsp. cremoris MG1363 (NC_009004.1 (311092..312831); Gene ID: 4798592) was used as the 
query sequence for a protein blast (blastp) analysis (http://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Pro-
teins) applying default settings. Due to redundancies of transporters from the same organism or strain, 
the 100 closest homologues of LmrC were reduced to 45 sequences. The gene lmrD was found 
directly adjacent to lmrC in the same operon, building a bicistronic expression cassette. The same 
arrangement was observed for the other transporters. Some of the transporters were not only 
adjacent, but even overlapping. Two examples of such a grouping are shown in Figure 1a. 
2.2.2 Regional order neural network (RONN) analysis 
These 45 heterodimeric ABC transporters were all of prokaryotic origin and were further validated by a 
structural biology server from the University of Oxford (http://www.strubi.ox.ac.uk/RONN). Each chain 
was analyzed separately. The server detects natively disordered regions in proteins which may affect 
solubility and crystallizability(18). As an output, RONN predicts the probability for each amino acid (aa) 
to be disordered by providing a value between 0 and 1. We exploited this output by adding penalty 
points. Disorder probability values of ≥ 0.5 received one penalty point/aa; values of ≥ 0.6 were 
punished with three penalty points/aa and values of ≥ 0.7 were given ten penalty points/aa. The 25 
best performing transporters in this analysis were chosen to search for the availability of genetic 
material. The penalty points were summed up and are shown for the final selection of transporters 
(Table 1). 
2.2.3 Preparation of genomic DNA from cell pellets 
Both the “Deutsche Sammlung von Mikroorganismen und Zellkulturen” (DSMZ) and the American 
Type Culture Collection (ATCC) were searched to obtain genetic material of these 25 transporters in 
the form of genomic DNA (gDNA) or as cell pellets. The gDNA from Enterococcus faecalis V583 was 
ordered from ATCC (ATCC 700802D-5). The gDNA from Thermotoga maritima MSB8 (ATCC 43589D-
2) was used before in our lab (Dissertation Daniel Frey). Cell pellets from Bacillus subtilis subsp. 
subtilis str. 168 (DSM4424), Dictyoglomus thermophilum H-1-12 (DSM3960), Dictyoglomus turgidum 
(DSM6724), Lactobacillus gasseri ATCC33323 (DSM20243 [63 AM]), Thermotoga petrophila RKU-1 
(DSM13995), Thermotoga sp. RQ2 (DSM4138), Listeria welshimeri serovar 6b str. SLCC5334 
(DSM20650) and Thermotoga neapolitana (DSM4359) were ordered from DSMZ. The gDNA from the 
cell pellets was extracted with the help of the GenEluteTM Bacterial Genomic DNA Kit (Sigma Aldrich, 
NA2100-1KT) according to the manufacturer’s protocol. Plasmids encoding the two transporters 
PatAB (Streptococcus pneumoniae R6) and LmrCD (Lactococcus lactis subsp. cremoris MG1363) 
were kind gifts of H. van Veen (Department of Pharmacology, University of Cambridge). 
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2.2.4 Gene amplification and cloning into pBXC3GH and pBXNH3 
All the below specified transporter genes were amplified directly from the purchased or extracted 
gDNA by polymerase chain reaction (PCR). Exceptions are the two transporters PatAB and LmrCD, 
where the amplification was performed from the donated plasmids. All PCR products except the ones 
of PatAB (see below) were inserted in the FX-plasmids pBXC3GH and pBXNH3 for test 
expressions(20). Both, pBXC3GH and pBXNH3 are pBAD24 based expression vectors. In pBXC3GH 
the protein of interest (POI) is fused to a C-terminal green fluorescent protein (GFP) that is further 
connected to a deca-His-tag (3C PreScission protease cleavable) for purification purposes (Figure 1b, 
upper panel). In pBXNH3 the POI is fused to an N-terminal, cleavable deca-His-tag (Figure 1b, lower 
panel). The primers used for the amplification of the transporters for the FX-cloning are listed below. 
One forward and one reverse primer were used to amplify the heterodimeric transporters as bicistronic 
gene operon. In contrast to the genes listed, PatAB is encoded on distinct locations on the 
chromosomal DNA. The preparation of the special expression vector pBAD24_duet and the cloning 
and expression of PatAB are described in the following sections.  
 
TM287/288 from Thermotoga maritima: 
5’-ATATATGCTCTTCTAGTAAAACACTCGCCAGATATTTAAAGC-3’ 
5’-TATATAGCTCTTCATGCTTCTTTTTCTACAACGAGACCGTATTGG-3’ 
Tpet from Thermotoga petrophila: 
5’-ATATATGCTCTTCTAGTAAAACACTCGCCAGATATTTAAAACCTTACTGGC-3’ 
5’-TATATAGCTCTTCATGCTCTTTCTACAACGAGACCG-3’ 
TRQ from Thermotoga sp. RQ2: 
5’-ATATATGCTCTTCTAGTAAAACACTCGCCAGATATTTAAAGCCG-3’ 
5’-TATATAGCTCTTCATGCTCTTTCTACAACGAGACCGTATTGGC-3’ 
CTN from Thermotoga neapolitana: 
5’-ATATATGCTCTTCTAGTAGAACGCTTGCAGGCTATCTTAAGCC-3’ 
5’-TATATAGCTCTTCATGCTCTTTCTACAACGAGACCG-3’ 
EF1 from Enterococcus faecalis V583: 
5’-ATATATGCTCTTCTAGTAAAGTATACAAAAAATTATTTAGTTATGTCCC-3’ 
5’-TATATAGCTCTTCATGCTCGTGATTGAGCTTCTTTTTCATAGACG-3’ 
EF2 from Enterococcus faecalis V583: 
5’-ATATATGCTCTTCTAGTGACCTTATTATTCAACACGCC-3’ 
5’-TATATAGCTCTTCATGCTTCAAAAACAAATTGATTTTTATAAAGTTCCGC-3’ 
Lwe from Listeria welshimeri serovar 6b str. SLCC5334: 
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5’-ATATATGCTCTTCTAGTAAAGTATTGTTTCACCATCTC-3’ 
5’-TATATAGCTCTTCATGCTTCAATAACGAATTGATTATGATATAGC-3’ 
BmrCD from Bacillus subtilis subsp. subtilis str. 168: 
5’-ATATATGCTCTTCTAGTTTTTCAGTTTTGAAAAAGCTTGGC-3’ 
5’-TATATAGCTCTTCATGCTGCAATGGAATGTTTCTGTCCC-3’ 
Dtur from Dictyoglomus turgidum: 
5’-ATATATGCTCTTCTAGTAGAAAACTTTTGAAGTTTTTAAAACC-3’ 
5’-TATATAGCTCTTCATGCTTTTATTTCTACTTCATCGGC-3’ 
DICT from Dictyoglomus thermophilum H-1-12: 
5’-ATATATGCTCTTCTAGTAAAAAACTTTTGAAATTTTTAAAACC-3’ 
5’-TATATAGCTCTTCATGCTTTTATTTCCACTTCGTCGGC-3’ 
LGAS from Lactobacillus gasseri ATCC33323: 
5’-ATATATGCTCTTCTAGTCAGATTTTGAAGCCACAC-3’ 
5’-TATATAGCTCTTCATGCTTCAAATGCCATTTGATTAGTATATAGTCCG-3’ 
LmrCD from Lactococcus lactis subsp. cremoris MG1363: 
5’-ATATATGCTCTTCTAGTATTTTCAAATCAATCATGAAGCATAAATG-3’ 
5’-TATATAGCTCTTCATGCTTCAAAAACGAATTGATTATGATAAAG-3’ 
 
FX cloning, a simple one cup cloning method was performed as described by Geertsma et al.(20). 
Briefly, the gel purified PCR product was mixed with the selected FX vector (pBXNH3 or pBXC3GH) 
and incubated with the SapI restriction enzyme for one hour at 37 °C. After inactivation of the enzyme, 
ligase and ATP were added to the mixture and incubated for another hour at 25 °C. After a final 
inactivation step the mixture was directly used to transform E. coli. All the reactions were performed in 
a standard PCR machine. 
2.2.5 Small scale expression and whole cell in gel analysis 
The constructs pBXC3GH_TM287/288, pBXC3GH_Tpet, pBXC3GH_TRQ, pBXC3GH_CTN, 
pBXC3GH_EF1, pBXC3GH_EF2, pBXC3GH_Lwe, pBXC3GH_BmrCD, pBXC3GH_Dtur, 
pBXC3GH_DICT, pBXC3GH_LGAS and pBXC3GH_LmrCD were transformed into the Escherichia 
coli expression strain C43(DE3). A preculture was grown for each construct. The preculture was used 
1:40 to inoculate 1 ml 2YT expression cultures in a 96-well plate. Cells were grown at 30 °C for three 
hours and then induced for another three hours at three different L-arabinose inducer concentrations 
of 10-1, 10-3 and 10-5 % (w/v). After centrifugation, the cells were resuspended in 50 mM KPi pH 7.2, 1 
mM MgSO4, 10 % (v/v) glycerol, 1 mM PMSF and traces of DNase(21). Glass beads (300 mg, acid-
washed, ≤ 106 µm, Sigma G4649) were added to each 1 ml culture and the cells were disrupted with a 
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Fast Prep device for two times 20 seconds at force 6 with five minutes cooling on ice in between. 40 µl 
of the supernatant were taken and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) loading dye was added. The samples were separated by SDS-PAGE and the gels were then 
analysed in a LAS-3000 imaging system (Fujifilm). The Precision Plus ProteinTM Dual Color Standards 
(Bio-Rad) was loaded as size marker. The two bands at 25 kD and 75 kD are colored and show a 
fluorescence signal (Figure 2). 
2.2.6 Comparison of expression levels and purification yields of selected GFP-
constructs 
The five best expressing transporter-GFP fusion constructs were transformed in C43(DE3) and the 
proteins were expressed as described above, but this time in 1.2 litre expression cultures. 
pBXC3GH_Dtur, pBXC3GH_EF2, pBXC3GH_LmrCD, pBXC3GH_TM287/288, pBXC3GH_BmrCD 
were selected for this experiment. The cells were lysed by three passages through a French press in 
20 mM Tris pH 8, 200 mM NaCl. The buffer was additionally supplemented with 2 mM MgCl2 and 
DNase (Sigma). Undisrupted cells were removed by centrifugation at 8’000 rpm for 15 min in a SS34 
rotor. Cell membranes were obtained by ultracentrifugation in a Beckman Ti70 rotor at 40’000 rpm for 
40 min. This pellet was then resuspended in 50 mM Tris pH 7.4, 150 mM NaCl and 10 % (v/v) glycerol 
and solubilized by the addition of 1.5 % (w/v) n-dodecyl-β-D-maltopyranoside (β-DDM, Glycon) for 2 
hours. Unsolubilized material was removed by ultracentrifugation for 30 min at 45’000 rpm. The 
soluble supernatant was loaded onto Ni2+-NTA agarose gravity flow columns (Qiagen). The columns 
were then washed with 30 mM imidazole pH 7.5, 200 mM NaCl, 10 % (v/v) glycerol and 0.03 % (w/v) 
β-DDM. The transporters were eluted from the column with 200 mM imidazole pH 7.5, 200 mM NaCl, 
10 % (v/v) glycerol and 0.03 % (w/v) β-DDM. Protein from the same amount of cells were separated 
by SDS-PAGE and analysed via in gel fluorescence in the LAS-3000 imaging system, as described 
above and Coomassie staining (Figure 3). 
2.2.7 Expression vector pBAD24_duet for PatABHis and PatAHisB expression 
Two primers were designed to amplify the regulatory elements from pBAD24, which include the AraC 
binding sites, the promoter sequence and the Shine Dalgarno sequence. The forward primer inserts a 
SalI restriction site. The reverse primer was initially designed to be 133 base pairs (bp) long and was 
therefore divided into two smaller, overlapping primers. Reverse primer 1 inserts a 3C PreScission 
protease cleavage site and a deca-His-tag. The first PCR with the pBAD24_duet forward primer and 
the pBAD24_duet reverse primer 1 amplifies a product of 384 bp. This fragment was purified from an 
agarose gel and used for the second PCR with the primers pBAD24_duet forward and the 
pBAD24_duet reverse primer 2. The second reverse primer inserts a HindIII, a SbfI and a KpnI 
restriction enzyme site, plus a glycine-serine linker. The resulting fragment from the second PCR had 
a length of 439 bp. The second, purified PCR fragment plus the vector pBAD24 were SalI and HindIII 
digested and ligated to yield the pBAD24_duet vector. The two genes patA and patB were cloned in 
the two possible combinations PatABHis and PatAHisB into this arabinose-based expression vector via 
the restriction sites NcoI/XmaI and KpnI/SbfI, respectively. First, the fragment with the flanking two 
restriction sites NcoI/XmaI was ligated. This removes a KpnI site, which is a prerequisite that the 
 19  
 From many to few  
second KpnI/SbfI fragment can be ligated. The primers for the amplification of the two genes patA and 
patB and the primers for the pBAD24_duet construction are listed below. A summary of the cloning 
procedure is given in Figure 4. 
 
pBAD24_duet forward: 
5’-ATATGTCGACAGAAACCAATTGTCCATATTGCATCAGACATTGCCG-3’ 
pBAD24_duet reverse primer 1: 
5’-CCCTGGAACAGAACTTCTAGATGATGGTGATGGTGATGGTGATGGTGATGGCTCATGGTGAAT 
TCCTCCTGCTAGCCC-3’ 
pBAD24_duet reverse primer 2: 
5’-ATATAAGCTTCCTGCAGGGGTACCAGAACCGCCACCGCCGCCGGAACCACTCGGCCCCTGGA 
ACAGAACTTCTAG-3’ 
 
PatABHis from Streptococcus pneumoniae R6: 
PatA: 5’-ATATCCATGGGCCTGATTCAGAAAATAAAAACC-3’ 
5’-ATATCCCGGGTCATTTCTGTGTTTCATAGATTTCACGG-3’ 
PatB: 5’-ATATGGTACCAAGACAGTTCAATTTTTTTGGC-3’ 
5’-ATATCCTGCAGGTTATTCGAAAACAAATTGATTGTG-3’ 
PatAHisB from Streptococcus pneumoniae R6: 
PatA: 5’-ATATGGTACCCTGATTCAGAAAATAAAAACC-3’ 
5’-ATATCCTGCAGGTCATTTCTGTGTTTCATAGATTTCACGG-3’ 
PatB: 5’-ATATCCATGGGCAAGACAGTTCAATTTTTTTGGC-3’ 
5’-ATATCCCGGGTTATTCGAAAACAAATTGATTGTG-3’ 
2.2.8 Expression and purification of the pBXNH3 constructs 
The pBXNH3 constructs were transformed into E. coli C43(DE3) cells and the proteins were 
expressed and purified as described above for the pBXC3GH constructs. After elution from the Ni2+-
NTA column the protein was concentrated to 2.5 ml using an Amicon Ultra-4 or Ultra-15 concentrator 
unit (Millipore) with a molecular weight cut-off of 50 kDa and then incubated over night with 3C 
PreScission protease (1:10 (w/w), GE healthcare) at 4 °C. After the digest, the transporter samples 
were desalted (PD-10, Amersham Biosciences) to remove imidazole. Afterwards the proteins were 
reloaded on a Ni2+-NTA column to remove the cleaved deca-His affinity tag and the hexa-His affinity 
tagged 3C protease. To recapture the transporters quantitatively from the rebinding step, 30 mM 
imidazole had to be added to the elution buffer. The protein was then concentrated and separated by 
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size exclusion chromatography (Superdex 200 column (GE Healthcare)) in 20 mM Tris pH 7.5, 150 
mM NaCl, 0.03 % β-DDM. Figure 5 shows the SEC profiles of the transporters expressed from the 
pBXNH3 constructs and Table 1 summarizes the molecular weights of the individual half-transporters. 
2.2.9 Limited tryptic digest analysis 
To further test the stability of the selected transporters a limited tryptic digest was performed. The 
purified transporters (2.2 µg) from SEC were mixed with trypsin in ratios 1:5’000, 1:500 or 1:25 (w/w), 
incubated for 30 minutes at 30 °C and then separated via SDS-PAGE. The gels were analysed by 
Coomassie Brilliant Blue R-250 staining. 
2.2.10  Crystallization and diffraction analysis 
After size exclusion chromatography (SEC) the fractions from the main peak of the transporters were 
combined and concentrated to 14-16 mg/ml using an Amicon Ultra-4 concentrator unit (Millipore) with 
a molecular weight cut-off of 50 kDa. The proteins were then mixed 1:1 (100 nl droplets) with the 
mother liquor in MRC 2 Well Crystallization Plates (Swissci) and incubated in a Crystal farm at 20 °C. 
All described manipulations were performed by the NCCR high throughput Crystallization Facility. Dtur 
was crystallized in 50 mM Na-acetate pH 5.5, 0.5 M NaCl and 11 % (w/v) poly ethylene glycol (PEG) 
4’000. Prior to flash-freezing, the crystals were cryo-protected in mother liquor containing 30 % 
ethylene glycol (EG, v/v) and 0.03 % β-DDM (w/v). TRQ crystallized in 50 mM glycine pH 9.4, 200 mM 
CaCl2 and 35 % (v/v) PEG 400. Due to high concentrations of PEG 400, the crystals could be frozen 
directly without further cryo-protection. Tpet crystallized in 50 mM 2-[(2-amino-2-oxoethyl)-
(carboxymethyl)amino]acetic acid (ADA) pH 6.5, 50 mM zinc acetate and 25 % (v/v) PEG 400 and 
crystals were frozen without further cryo protection. The Thermotoga transporter TM287/288 formed 
crystals in 29 % (v/v) polyethylene glycol (PEG) 400, 50 mM Na-cacodylate pH 5.5 and 100 mM CaCl2 
(low CaCl2 form) and by the addition of 3 mM MgCl2 and 2.5 mM AMP-PNP. Another more lens-like 
crystal form was obtained for TM287/288, but instead of the 100 mM CaCl2, higher concentrations of 
300 – 600 mM CaCl2 (high CaCl2 form) and PEG 400 concentrations of 32 – 39 % (v/v) were used. No 
cryoprotectant was added to freeze the TM287/288 crystals. EF2 crystals were obtained in 100 mM 
NaCl pH 9.5, 50 mM glycine and 33 % (v/v) PEG 300. These crystals were as well frozen directly. 
Diffraction data were collected at the protein crystallography beamline X06SA at the Swiss Light 
Source (SLS) of the Paul Scherrer Institut (PSI) (Figure 9) and processed using the program XDS(27). 
For Dtur, molecular replacement with a homology model (SWISS-MODEL(24)) based on the structure 
of TM287/288 using Phaser(25) was successful. For TRQ, molecular replacement using the structure 
of TM287/288 with manually mutated side-chains (COOT) was performed successfully (Figure 10). 
The sequence of TRQ obtained from sequencing and the sequence deposited in the databank differ in 
some amino acid positions. Figure 11 shows the alignment of TM287/288, Tpet and TRQ 
(sequencing). Molecular replacement with the TM287/288 structure (low CaCl2) was successful for 
TM287/288 (high CaCl2 form). In addition, a round of refinement using the program PHENIX(26) was 
performed. The analysis of the crystallographic data is summarized in Table 2. 
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2.3 Results 
2.3.1 Selection of potentially stable LmrCD homologues based on peptide 
disorder prediction 
The expression and purification to homogeneity of the multidrug transporter LmrCD from Lactococcus 
lactis have been described previously (16). However, all our attempts to crystallize this transporter, 
when purified from Lactococcus lactis or Escherichia coli membrane vesicles did not result in crystals. 
To search for homologues more suitable to x-ray crystallography we performed a protein blast (blastp) 
using the primary sequence of LmrC as the query sequence (Material and Methods)(17). The lmrD 
gene directly follows lmrC on the chromosome and the two genes constitute an operon. The genes of 
some half-transporters even overlap. Figure 1a shows two examples of such a bicistronic 
arrangement. The output from the blast search, minimized to 45 non-redundant sequences from 
different organisms or strains, was further analysed by the online bioinformatics tool RONN that 
predicts natively disordered regions of proteins(18). Based on sequence analysis by RONN the 
number of possible constructs could be decreased to 25 (Materials and Methods). The last selection 
criterion was the availability of genomic DNA, which again restricted the number of homologues to a 
total of twelve. The finally chosen homologues for further biochemical analysis were TM287/288 from 
Thermotoga maritima, Tpet624/625 from Thermotoga petrophila (Tpet), TRQ2649/650 from 
Thermotoga sp. RQ2 (TRQ), CTN396/397 from Thermotoga neapolitana (CTN), EF583/584 from 
Enterococcus faecalis (EF1), EF789/790 from Enterococcus faecalis (EF2), Lwe2699/2700 from 
Listeria welshimeri (Lwe), YheHI from Bacillus subtilis (BmrCD), Dtur641/642 from Dictyoglomus 
turgidum (Dtur), DICT477/478 from Dictyoglomus thermophilum (DICT), LGAS525/526 from 
Lactobacillus gasseri (LGAS) and PatAB from Streptococcus pneumoniae. The identities to LmrCD 
(%) of the above listed transporters are shown in Table 1 and a phylogenetic tree is shown in Figure 
12. 
2.3.2 GFP-fusion proteins and in gel fluorescence 
Recombinant membrane protein production for functional and structural studies is often hampered by 
low expression levels(19). Therefore the proteins often have to be expressed in large fermented 
cultures or well expressing and stable homologues have to be found. The evaluation of expression 
levels of a broader ensemble of proteins of interest (POIs) is often performed at smaller scale. The 
standard technique for the detection of such small amounts of protein is typically Western blotting, 
which is however comparatively time consuming and relies on good antibodies. We decided to use a 
high-throughput in gel fluorescence detection method, which is based on the GFP-fusion expression 
vector pBXC3GH(20). The resulting translated protein is schematically shown in Figure 1b (upper 
panel). This construct combines the detection of properly folded protein monitored by GFP-
fluorescence with the SapI restriction enzyme dependent one cup fragment exchange (FX) cloning 
technique(20, 21). pBXC3GH is a derivate of pBAD24 and is therefore L-arabinose inducible. Figure 2 
shows the small scale expression tests using three different inducer concentrations. The evaluated 
transporters are TRQ, BmrCD, Tpet, CTN, EF2, LGAS, DICT, Dtur, TM287/288 and Lwe. An 
expression level variability is visible on the gels that seems to be dependent on the inducer 
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concentration. TM287/288 for example shows a significant difference of the expression level between 
the different inducer concentrations. At a concentration of 10-5 % L-arabinose the induction is too 
weak. At a concentration of 10-3 L-arabinose the yield is significantly higher. If one increases the 
inducer concentration again by a factor one hundred, the expression decreases again which is most 
probably the result of an overload of the folding machinery, resulting in major amounts of badly folded 
protein which does not insert into the membrane. Dtur and EF2 are other examples behaving in a 
similar way as TM287/288.  
The best expressing homologues Dtur, EF2, TM287/288, BmrCD and LmrCD were subsequently 
expressed at larger scale (1.2 l culture), purified by Ni2+-NTA and separated via SDS-PAGE. Protein 
purified from the same amount of cells was loaded on the polyacrylamide gel. Figure 3 shows purified 
transporters by in gel fluorescence and Coomassie staining. LmrCD and TM287/288 appear to be 
expressed at a lower level than the other three transporters. All five transporters were purified as 
stable heterodimers by virtue of a His-tagged GFP fused to the C-terminus of the second half-
transporter (Figure 1b).  
2.3.3 The construct pBAD24_duet for PatABHis and PatAHisB expression 
The two genes patA and patB are arranged differently than the genes of the other analysed 
transporters (Figure 1a), because they are separated by a transposable element on the genomic DNA 
(gDNA). Therefore the genes had to be amplified separately and not as a single bicistronic cassette. 
For the expression of PatABHis and PatAHisB a special vector, named pBAD24_duet was designed 
(Materials and Methods). This vector allows for the coexpression of two genes from the same plasmid. 
Therefore a vector with two arabinose-inducible promoters (pBAD) both containing the regulatory AraC 
binding sites and the ribosome binding site (RBS) upstream of the promoter was constructed. Figure 4 
summarizes the whole cloning procedure. The pBAD24_duet expression vector for PatABHis and 
PatAHisB does not produce GFP-fusion proteins. 
2.3.4 pBXNH3 expression vector 
pBXNH3, a further FX-expression vector described in Geertsma et al. was additionally tested for 
LmrCD expression(20). The expression in this construct increased the expression levels of all tested 
proteins by a factor of at least two to three as compared to the pBXC3GH constructs (data not shown). 
In addition, 3C protease cleavage of an N-terminal His-tagged protein results in a shorter remaining 
overhang compared to a C-terminal His-tagged protein. Therefore the transporters CTN, Tpet, BmrCD, 
DICT, Dtur, TRQ, TM287/288, EF1 and EF2 were additionally cloned into pBXNH3. A schematic 
overview of a translated protein expressed from the pBXNH3 construct is shown in Figure 1b (lower 
panel). Lwe and LGAS were omitted for this analysis, because these two homologues did not show an 
appropriate expression level in the initial expression tests (Figure 2). All other nine transporters plus 
LmrCD were expressed and purified. In addition to the affinity column a size exclusion 
chromatography (SEC) step was added to the purification protocol. Furthermore the deca-His-tag was 
cleaved off by 3C PreScission protease. Figure 5 shows the gelfiltration runs for all the ten 
transporters that were considered for crystallization experiments. Most of these transporters elute as a 
monodisperse peak from the gelfiltration column corresponding to the molecular weight of a 
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heterodimer and fractions of the main peak were used for further proteolytic digest analysis or 
crystallization experiments. 
2.3.5 Limited tryptic digest 
Limited tryptic proteolysis is a simple method to test for stability and degradation of a protein(22). 
Preferably, highly accessible loops containing lysines or arginines are cleaved. Nine of the ten 
transporters were analysed by limited tryptic digestion. SEC-purified transporter samples were used 
for this experiment (upper gel, Figure 6). The dimers are highlighted by a red box. EF2 was not utilized 
in this analysis. The lower three gels in Figure 6 show the Coomassie stained SDS-PAGE gels from 
the tryptic digest analysis performed at increasing trypsin concentrations while the amount of each 
transporter was kept constant. There are two bands in all lanes running at a molecular weight higher 
than 70 kDa. These bands stem from two impurities purified along with all the transporters under 
investigation. The higher band presumably represents AcrB, a multidrug pump from Escherichia 
coli(23). The identity of the lower band is not known and was not investigated further. Most of the 
heterodimeric transporters show two bands on the SDS-PAGE gel (upper gel). CTN and EF1 are the 
two exceptions. In these cases, the monomers of the heterodimers either exhibit identical 
electrophoretic mobility, or the untagged chain B of the heterodimer was lost during purification. The 
SEC retention volume, corresponding to the molecular mass of a dimer rather supports the first 
assumption, namely an indistinguishable electrophoretic mobility (Figure 5). However, the purification 
of Chain A-homodimers cannot be excluded based on this analysis. For LmrCD only the upper band 
(LmrD) is clearly visible and the lower band (LmrC) is stoichiometrically underrepresented at 1:5000 
trypsin to protein ratio. This is a known phenomenon and can be explained by the degradation of 
LmrC, visible in the additional bands in this lane (Seeger et al., unpublished). At a trypsin to protein 
ratio of 1:500, CTN and EF1 are further degraded and LmrC has totally disappeared. All the other 
transporters show only minor degradation. At a trypsin to protein ratio of 1:25, Tpet, TRQ, TM287/288 
still show the characteristic two bands and DICT and Dtur are only partially degraded. Interestingly, 
four of these five highly trypsin-resistant transporters could be crystallized and showed diffraction 
around 10 Å or better. This analysis is shown below. 
2.3.6 Expression and SEC runs of the PatABHis and PatAHisB constructs 
As described above, we had to construct a special expression vector, named pBAD24_duet for the 
production of PatAB having the deca-his-tag attached either to PatA (PatAHisB) or PatB (PatABHis) 
(Figure 4). Figures 7a-c show the Ni2+-NTA, the SEC purification and the tag-cleavage of PatAHisB and 
PatABHis. When expressing PatABHis the two chains exhibit a different electrophoretic mobility on the 
SDS-PAGE (62250.7 kDa and 66445.8 kDa). In PatAHisB, where the tag, the cleavage site and the 
linker are connected with PatA, the two chains (65297.9 kDa and 65718.1 kDa) are inseparable with 
the method used (Figure 7a). Figure 7b shows the 3C PreScission protease cleavage experiments of 
PatAHisB and PatABHis. In this analysis it becomes apparent that PatAHisB effectively consists of two 
chains (lane 2). Two additional bands with a calculated molecular weight of 49427.5 kDa and 17036.2 
kDa for PatABHis, 48699.9 kDa and 17036.2 kDa for PatAHisB, respectively, can be observed in both 
lanes were the protease (calculated molecular weight: 21674.8 kDa) was added. These bands result 
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from the unspecific cleavage of PatB by the 3C protease. Both, uncleaved PatAHisB and PatABHis show 
a monodisperse peak in SEC (Figure 7c). Figure 7d shows the sequence of PatB from PatABHis and 
highlights, C-terminal to the deca-his-tag, the 3C protease recognition site (LEVLFQGP) in red. The 
cleavage site is indicated by a blue vertical line. A second, non-canonical 3C cleavage site (..VLF.G.) 
further downstream is highlighted in red and a possible cleavage site is indicated in blue. Partial 
cleavage of this non-canonical cleavage site results in the two additional cleavage products seen in 
Figure 7b. 
2.3.7 Crystallization and diffraction analysis 
Ni2+-NTA purified, tag-cleaved and SEC-purified Tpet, TRQ, TM287/288, DICT, Dtur, BmrCD and EF2 
were set-up for crystallization experiments using the in house NCCR crystallization facility. Dtur, TRQ, 
Tpet, TM287/288 and EF2 all formed diffracting protein crystals. Figure 8 shows the obtained crystals 
for all these homologues. The crystals were fished and flash-frozen in liquid nitrogen and measured at 
the Swiss Lightsource (SLS) of the Paul Scherrer Institut (PSI) (Materials and Methods). Figure 9 
shows the diffraction patterns collected for Dtur, TRQ, Tpet, TM287/288 and EF2, respectively. For 
TM287/288 two different crystal forms were obtained, one at high and the other at low CaCl2 
concentration, belonging to different space groups. Dtur diffracted to 7.4 Å, TRQ to 3.6 Å, Tpet to 
about 8.5 Å, TM287/288 (low CaCl2 form) to 2.9 Å, TM287/288 (high CaCl2 form) to 4.6 Å and EF2 to 
about 14.5 Å. For Dtur, TRQ and TM287/288, complete datasets were collected that allowed for data 
processing and determination of the space group. For TM287/288 (low CaCl2 form) the structure could 
be solved, which is described in Chapter 3(11). Table 2 summarizes the molecular replacement and 
refinement results. Figure 10 shows the arrangement of the heterodimers Dtur versus TRQ and versus 
TM287/288 (high CaCl2 form). 
2.4 Discussion 
Membrane proteins and especially membrane transporters are a class of proteins that are difficult to 
produce and even more difficult to crystallize. This is because transporters are very flexible which is a 
prerequisite to full-fill their task in cycling from one conformation into another one to shuttle their 
substrate across the plasma membrane. A successful strategy to crystallize a certain membrane 
protein of interest is to clone and express many homologous proteins to search for those with 
favourable biophysical and biochemical properties. High-throughput cloning methods facilitate the 
construction of the large number of necessary genetic constructs. We were interested in obtaining 
structural and functional information for a special class of ABC exporters, namely the subclass of 
heterodimeric exporters. We selected the well-characterized prokaryotic heterodimeric ABC 
transporter LmrCD for Lactococcus lactis as our starting molecule. However all attempts to crystallize 
LmrCD purified from Lactococcus lactis or from Escherichia coli membrane vesicles did not result in 
any crystals. For this reason we searched for a more stable homologue with better biophysical 
properties. After searching for suitable homologues in the databank, performing a disorder prediction 
and a limited tryptic digest analysis we cloned several transporters using the high-throughput fragment 
exchange (FX) cloning technique. With this attempt we were able to express and purify 13 transporters 
and were able to crystallize almost half of them. However, the three Thermotoga transporters (TRQ, 
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Tpet and TM287/288) share a high sequence identity (Figure 11 and Figure 12) and TRQ was 
crystallized in the same space group with similar cell edges as TM287/288. Therefore, these 
Thermotoga transporters should be regarded as one hit only. We were able to solve the structure of 
the heterodimeric ABC exporter TM287/288 from Thermotoga maritima at a resolution of 2.9 Å. This 
was the first structure solved from the subclass of heterodimeric ABC transporters(11) and now serves 
as a model system to study ABC exporters of pathogenic bacteria (PatAB, EF1, EF2) and medically 
relevant eukaryotic transporters such as Tap1/2, MRP1, CFTR and SUR1.  
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TABLE 1 | PROTEIN PARAMETERS 
Transporter Identities 
to LmrCD 
(%) 
RONN 
(penalty 
points) 
Mw (g/mol) * 
Chain A 
(# amino acids) 
Mw (g/mol) * 
Chain B 
(# amino acids) 
Crystallizability 
CTN 37.8% 224 67186.4 (604) 67959.3 (598) - 
Tpet 37.8 % 207 67267.4 (604) 67764.2 (598) + 
BmrCD 29.3 % 295 67970.5 (612) 76376.1 (674) - 
DICT 37.8 % 134 67866.1 (604) 70482.1 (621) - 
Dtur 37.3 % 108 67993.1 (604) 70182.8 (621) + 
LmrCD 100 % 329 66733.1 (606) 73997.7 (664) - 
TRQ 37.7 % 208 67297.5 (604) 67750.1 (598) ++ 
TM287/288 37.7 % 216 67219.4 (604) 67779.2 (599) ++ 
EF1 25.1 % 115 69097.5 (611) 65700.0 (581) - 
EF2 55.2 % 179 65698.5 (598) 66223.1 (590) + 
PatABHis 
PatAHisB 
56.6 % 90 62250.7 (565) 
65297.9 (594) 
68765.3 (618) 
65718.1 (589) 
- 
*The molecular weights (MW) are calculated with uncleaved Deca-His-tag. 
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TABLE 2 | DATA COLLECTION 
 Dtur 
 
TRQ TM287/288 
(low CaCl2 form) 
TM287/288 
(high CaCl2 form) 
Data Collection 
    
Space group P21 C2 C2 P3121 
Cell dimensions     
a, b, c (Å) 161.91     
93.37    
172.35   
213.01 
83.81 
111.05 
216.33 
84.31 
115.78 
118.15 
118.15 
272.46 
α, β, γ (º)  90.000   
99.156   
90.000 
90.000   
95.315   
90.000 
90.000 
91.200 
90.000 
90.000 
90.000 
120.000 
Resolutiona) (Å) 7.4  
(7.59-7.40) 
3.6 
(3.69-3.60) 
2.9 
(2.98-2.90) 
4.7 
(4.82-4.70) 
Rmerge (%) 8.0 (98.2) 10.0 (77.4) 4.8 (71.7) 6.1 (91.9) 
I/σI 13.76 (2.27) 8.02 (1.77) 24.14 (3.54) 25.07 (4.24) 
Completeness (%) 96.8 (99.8) 92.0 (94.2) 99.5 (99.6) 99.8 (100) 
Redundancy 6.7 (6.8) 2.7 (2.6) 6.8 (6.8) 19.1 (18.8) 
Molecular Replacement 
    
LLG (log-likelihood gain) 353 4561 n.d. 1182 
TFZ (the translation function Z-score) 11.9 18.2 n.d. 24.7 
Water content (%) 48.03 66.92 n.d. 70.27 
Molecules/ASU (asymmetric unit) 2 1 1 1 
Refinement 
    
Rwork/ Rfree n.d. 24.82/28.98 21.70 / 26.32 31.97/46.36 
a) Highest resolution shell is shown in parenthesis. Not determined (n.d.) 
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4.1 Introduction 
ATP binding cassette (ABC) transporters are primary active transporters that use the energy of ATP 
binding and hydrolysis to shuttle a plethora of substrates across cellular membranes. They exist as 
importers and exporters. Whereas ABC importers are found in prokaryotes, ABC exporters exist both 
in prokaryotes and in eukaryotes(1). Importers are important for nutrient uptake, e.g. sugars, or for the 
supply of trace elements to the cell, such as metals. These membrane embedded transporters fulfil 
their task by interacting with a soluble, high-affinity periplasmic substrate binding protein. The 
physiological role of prokaryotic ABC exporters is less clear and only few substrates are known. MsbA, 
an ABC exporter in gram-negative bacteria is a lipid flippase, transporting lipid A and 
lipopolysaccharides (LPS) from the cytoplasmic side to the periplasmic side of the inner membrane. In 
addition, ABC exporters have been shown to be associated with multidrug resistance (MDR). In 
bacteria they were found to be responsible for extrusion of antimicrobial substances (PatAB, 
LmrCD)(2, 3) and in eukaryotic cells for the export of anticancer drugs (MRP1 and P-glycoprotein (P-
gp))(4, 5). Additionally, some ABC exporters are connected to common hereditary diseases like cystic 
fibrosis (CFTR) or neonatal diabetes (SUR1).  
The core of ABC transporters is built up by four domains, two transmembrane domains (TMDs) and 
two nucleotide binding domains (NBDs). The TMDs are responsible for substrate interaction and 
translocation and the NBDs provide the energy for the conformational changes within the TMDs 
necessary for providing alternative access to the substrate cavity. Binding of two ATP molecules to the 
motor domains (NBDs) leads to their dimerisation. This movement is transmitted to the TMDs via the 
coupling helices, which orient the TMDs outward-facing. The hydrolysis of ATP and the sequential 
release of inorganic phosphate (Pi) and ADP reset the TMDs again in an inward-facing conformation. 
Conserved motifs from both NBDs are responsible for the interaction with the nucleotides in a head-to-
tail manner. The A-loop, a conserved aromatic residue makes favourable pi-pi-stacking interactions 
with the aromatic adenine ring(6). The Walker A motif of one NBD and the ABC signature motif of the 
other NBD and vice versa sandwich the γ-phosphate moiety of the nucleotides. A conserved 
glutamate and histidine from the Walker B and the switch motif, respectively, together constitute a 
catalytic dyad responsible for ATP hydrolysis. In heterodimeric ABC transporters the Walker B and 
switch motif sequences often depart from the consensus sequence. This catalytic site is therefore 
called the degenerate site. In addition, heterodimeric transporters deviate in the signature motif and 
the D-loop sequence at the degenerate site (Figure 1). The Q-loop glutamine interacts with the γ-
phosphate moiety of the nucleotide and links the hydrolysis site with the TMDs via the coupling 
helices. And last but not least, the D-loop has been proposed to link the two hydrolysis sites of the two 
NBDs and thus might play a role in interdomain communication(7). We reported previously on the 
structure of the heterodimeric ABC transporter TM287/288 with one molecule of AMP-PNP bound 
asymmetrically to the degenerate site. In this inward-facing structure the NBDs remain in close contact 
which is mainly mediated by D-loop interactions at the degenerate site(8).  
Here we present the apo structure of the heterodimeric ABC transporter TM287/288 solved at a 
resolution of 2.53 Å. The apo TM287/288 structure shows an inward-facing conformation similar to the 
AMP-PNP bound structure of TM287/288(8). In addition, the model of the nucleotide-bound structure 
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was refined to a resolution of 2.6 Å. The two high resolution structures of TM287/288 with and without 
bound nucleotide allow for the first time the comparison of conformational changes occurring in the 
NBDs upon nucleotide binding in a full-length ABC exporter. This sheds light on the long lasting 
question regarding rigid-body movements between the α-helical and the RecA-like subdomain in 
NBDs. Furthermore the structures suggest that complete NBD disengagement is not a prerequisite for 
nucleotide exchange in ABC exporters. The two structures allow interesting conclusions about the 
interdomain communication between the two NBDs via both D-loops.  
4.2 Materials and Methods 
4.2.1 Protein production, purification and crystallization 
Production and purification of TM287/288 was performed as described previously for the AMP-PNP 
structure(8). Well diffracting crystals of TM287/288 in a nucleotide-free (apo) state were obtained by 
the vapor diffusion method in sitting drops at 20 °C against a reservoir containing 26 % (w/v) 
polyethylene glycol (PEG) 400, 50 mM Na-cacodylate pH 5.5 and 50 mM CaCl2. The crystallization 
set-ups were performed in the presence of 2.5 mM ADP and 3 mM MgCl2. Interestingly, ADP binding 
was not observed in the solved structure. Crystals of TM287/288 were also obtained in the complete 
absence of nucleotides and MgCl2 and grew against a reservoir containing 25 % PEG 400, 50 mM N-
(2-acetamido)iminodiacetic acid (ADA) pH 6.5 and 50 mM Zn-acetate. These crystals diffracted to 3.5 
Å and their structure (Rwork=22.6 % and Rfree=28.8 %, not deposited) was indistinguishable to the high 
resolution apo structure presented in this manuscript.  
4.2.2 Data collection and processing 
All crystals were frozen without further cryo protection. Diffraction data were collected at the protein 
crystallography beamline X06SA at the Swiss Light Source (SLS) of the Paul Scherrer Institut (PSI) 
and processed using the program XDS(9). Apo TM287/288 was crystallized in the same space group 
as the previously solved AMP-PNP bound TM287/288 and the structure was solved by molecular 
replacement using the program Phaser(10). The diffraction data exhibited strong anisotropy, and was 
therefore truncated using the online anisotropy server of the University of California Los Angeles using 
default settings(11), which lead to an improvement of the electron density maps. The density allowed 
for the building of the entire polypeptide chain with the exception of eight C-terminal residues of 
TM287 (residues 570-577), nine N-terminal residues of TM288 (residues 1-9) and five C-terminal 
residues of TM288 (residues 593-597). The AMP-PNP dataset was reprocessed and cut at a 
resolution of 2.6 Å. Side by side comparison of constant parts of the apo and the nucleotide-bound 
structures allowed for an iterative improvement of both models. Data collection and refinement 
statistics are listed in Table 1.  
4.2.3 Tilting angles between RecA-like and α-helical subdomain 
The type I importer MalFGK (PDBs 2R6G and 3PV0)(12, 13), the type II importer BtuCD (PDBs 4FI3, 
1L7V, 2QI9 and 4DBL)(14-17) and the exporter TM287/288 (PDBs …. and ….) were considered for 
this analysis. The apo structures (moving) were superimposed on the nucleotide-bound structures 
 64  
 Interdomain communication  
(fixed). First the RecA-like subdomains (four segments) were superimposed then the α-helical 
subdomains (four segments) were used for superimposition to determine the rotation angle between 
the RecA-like subdomain and the α-helical subdomain. The segments used for the superimposition 
are listed in Table 2. The program Superpose of the CCP4 Program Suite was utilized.  
4.3 Results 
4.3.1 Structure determination and superimposition with the AMP-PNP bound 
TM287/288 structure 
The apo crystal structure of the heterodimeric ABC exporter TM287/288 was solved as described in 
Materials and Methods. Apo TM287/288 was crystallized in the same space group as the AMP-PNP 
bound form (Table 1). Its structure was refined to 2.53 Å resolution (PBD .…, Rwork=23.9 % and 
Rfree=29.1 %) and shows an inward-facing conformation very similar to the one crystallized together 
with the non-hydrolysable ATP analogue AMP-PNP. The root-mean-square deviation (rmsd) between 
the Cα-positions of the TM287/288 structure with bound nucleotide (PDB …., new 2.6 Å structure, 
Rwork=22.68 % and Rfree=27.06 %) and the 2.53 Å structure without nucleotides is 0.636 Å over 
residues 1-569 (chain A) and 10-592 (chain B). Figure 2a depicts the full-length nucleotide-bound 
structure solved at 2.6 Å and highlights residues in red whose Cα-position deviate from the structure of 
the apo-state by more than 1.1 Å. Figure 2b shows the same analysis as in Figure 2a, but the 
deviations are highlighted on the 2.53 Å apo structure. Most differences are found in the NBDs and 
only few are observed in the transmembrane domains of the transporter. In addition, the majority of 
the deviations cluster at the degenerate nucleotide binding site around the bound nucleotide or at the 
interface of the two motor domains (Figure 2c). Influences by crystal packing interactions can be 
excluded, because both structures were crystallized in the same space group with basically identical 
cell edges. Figure 2d depicts the NBD in the same orientation as in Figure 2c, but instead of the 
structural deviations, conserved NBD motifs are shown. It is intriguing how well the differences 
between the two TM287/288 structures and the functionally important motifs co-localize. The analysis 
of the Cα-differences for NBD287 and NBD288 is additionally plotted as distances in Å vs. amino acid 
residue in Figure 3.  
  
 65  
 Interdomain communication  
4.3.2 Nucleotide binding domain 287 
The above analysis has shown that almost all differences between the full-length structures of 
TM287/288 in the two nucleotide states are found at the nucleotide binding domains. Therefore, a 
more thorough analysis was performed at the NBD level. Figure 4a shows a superimposition of the 
isolated NBD dimers of the two crystallized states (cyan and pink (AMP-PNP), white and gray (apo)). 
The root mean square deviation (rmsd) between NBD287 in the two states is 0.952 Å (over residues 
330-569). The rmsd of the corresponding two NBD288 is only 0.460 Å (over residues 353-592). 
Comparing the two NBD287s that provide the Walker A and the switch motif of the degenerate 
ATPase site in the apo and the nucleotide-bound form reveals structural differences that are strongly 
associated with conserved NBD motifs (Figure 2c and 2d). The whole loop (Arg340-Asp346) including 
Tyr341 (A-loop) is undergoing an outward movement of about 1.7 Å to accommodate the adenine 
moiety of AMP-PNP (Figure 4b and Figure 5a). The Walker A motif (GETGSGK in NBD287) that 
wraps around the nucleotide(7), shows differences in the Cα-positions of Gly369 and Ser373, which 
are in close proximity to the functionally important Walker A Lys372. The lysine itself undergoes only a 
slight rearrangement. More pronounced is the displacement of Leu375 (2.4 Å) and Met376 (2.7 Å), 
which are part of a α-helix directly following the Walker A motif (Figure 3a and Figure 5b). The Q-loop 
Gln414, which serves as a hinge between the α-helical and the RecA-like subdomain(18) shows a 
change in conformation in TM287/288 upon AMP-PNP binding. It flips into hydrogen bonding distance 
with the γ-phosphate hydroxyl group of the nucleotide (Figure 5c) and is involved in Mg2+ coordination. 
Its involvement in ATP sensing, which triggers inward rotation of the α-helical subdomain with respect 
to the RecA-like subdomain and more precisely the ATPase active site, respectively, has been 
suggested(19). Interestingly, this inward rotation of the helical subdomain is only very subtle in full-
length TM287/288 upon nucleotide binding (see below). The Walker B motif in NBD287 (VLILDD), 
deviating from the consensus sequence (ΦΦΦΦDE, Φ = aliphatic amino acid), shows a difference 
between the apo and nucleotide-bound structures in Asp494 (1.6 Å) and Asp495 (1.7 Å) and 
especially in the adjacent Cys496 (4.6 Å) (Figure 3a and Figure 5d). But by far the biggest difference 
upon nucleotide binding can be observed in the D-loop of NBD287 (SSVD), the adjacent Pro502 and 
the helix (Lys513-Lys517) following the D-loop. Ser498 moves 1.2 Å, Ser499 5.9 Å, Val500 even 7 Å 
and Asp501 3.3 Å. All these differences are associated with a pronounced conformational change of 
the D-loop (Figure 5e). In agreement with these observations, the D-loop of NBD287 shows a high B-
factor, reflecting its flexibility (Figure 6). However, electron density was sufficiently defined to allow 
model building. In contrast, in one of the four structures of ABCB10 (PBD 4AYW) the D-loop could not 
be traced completely, probably due to this high flexibility. A more detailed description of the D-loop of 
NBD287 and its interactions with the opposite NBD288 is given below in a separate section.  
4.3.3 Nucleotide binding domain 288 
Next to conformational changes in NBD287, minor changes are observed in NBD288 upon nucleotide 
binding. Figure 2c, Figure 3b and Figure 4c highlight these differences. A pronounced change two 
amino acids upstream (Thr438) of the Q-loop Gln436 in NBD288 is visible (Figure 5f). In the ABC-
specific signature motif (LSQGQ), which is involved in nucleotide binding in closed NBD dimers, 
Ser493 undergoes a conformational change upon AMP-PNP binding (Figure 5f). Nucleotide binding to 
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the degenerate site is responsible for the disruption of a hydrogen bond formed in the apo state 
between the signature motif Ser493 and the D-loop Asp523 of NBD288. In contrast to the large 
differences in the D-loop of NBD287 only a minor change in the D-loop of NBD288 (SNVD) in Ser520 
is observed (Figure 5f).  
4.3.4 Interdomain (nucleotide binding domains) interactions 
Nucleotide binding to full-length TM287/288 not only provokes changes within the NBDs, but also 
influences intermolecular interactions between the NBDs. Yuan et al. first described the intermolecular 
interplay between the signature motif of one NBD and the Walker A of the other NBD(19). In a closed 
NBD dimer, these two motifs form a composite hydrolysis site sandwiching the nucleotide in a head to 
tail manner. In the partially open NBD dimer of TM287/288 the signature motif is far apart from the 
AMP-PNP bound to NBD287. However, the D-loop of NBD288 (SNVD) intimately interacts with the 
nucleotide binding site of NBD287 and is part of the composite degenerate ATPase site. In the 
nucleotide-bound TM287/288 structure, the D-loop of NBD288 interacts via an extensive H-bond 
network with NBD287. The carbonyl oxygen of Ser520 makes a hydrogen bond to the ε-nitrogen of the 
H-loop Gln526. Gln526 is connected via an additional bond to the D-loop Asn521. Asn521 makes a 
direct contact to the bound AMP-PNP. Furthermore, Val522 and Thr524 of NBD288 establish each 
two H-bonds with Thr368 and Glu367, respectively, of the Walker A motif of NBD287 (Figure 7a, left). 
The removal of the nucleotide from the degenerate hydrolysis site results in a rearrangement of this H-
bond network. Ser520 remains connected to Gln526, but the H-bond between Gln526 and Asn521 is 
broken. Instead, Asn521 now makes a hydrogen bond to the Walker A Thr368. The two hydrogen 
bonds between Thr524 and Glu367 are preserved. Within NBD288, Asp523 of the D-loop forms an H-
bond with Ser493 of the signature motif in the apo form of TM287/288. In summary, the number of 
hydrogen bonds connecting NBD287 and NBD288 at the degenerate ATPase site is reduced from 
seven to four upon nucleotide removal (Figure 7b, left). Nevertheless, the NBDs remain in contact 
even in the absence of nucleotides, strengthening our earlier notion that the degenerate site is 
preformed to accommodate binding of the first nucleotide to the transporter(8).  
Nucleotide binding is associated with a pronounced movement of the D-loop and the connected D-
loop helix in NBD287 at the consensus site. It is fascinating to notice that this D-loop (SSVD) is 
actually more than 19 Å away from the site of nucleotide binding (measured between AMP-PNP γ-
phosphate and Cα of Asp501). The structural link between the bound nucleotide and the D-loop is in 
part established via the Walker B Asp495, which precedes the D-loop, separated by two residues and 
moves closer to the γ-Pi of AMP-PNP upon nucleotide binding (Figure 8). When AMP-PNP is bound, 
an interaction between Thr390 (NBD288) and the D-loop Asp501 is established (Figure 7a, right). 
Thr390 is part of the Walker A motif in NBD288 and is the corresponding residue to Thr368 (NBD287). 
Asp501 additionally interacts with the backbone nitrogen of Thr368. The switch residue His548 of the 
consensus ATPase site is too far away from the D-loop to interact in a similar way as the 
corresponding Q526 at the degenerate site. Nucleotide removal leads to a rearrangement of the D-
loop in NBD287 and disrupts the interaction of Asp501 with the Walker A of NBD288 (Figure 7b, right). 
The involvement of the D-loop in NBD-NBD interdomain communication has been postulated before 
based on structures of isolated NBDs(7). Here we show asymmetric interactions of the D-loops of 
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heterodimeric ABC exporters in the context of the full-length transporter structure. Our analysis reveals 
that the D-loop of the degenerate site plays a key role in the stabilization of the NBD interaction, 
whereas the D-loop at the consensus site is highly flexible and interacts with the opposite NBD only 
when a nucleotide is bound to the degenerate site. 
4.3.5 Nucleotide binding domain opening in inward-facing ABC exporter 
structures 
Three bacterial structures and five structures of eukaryotic origin in an inward-facing conformation 
have been deposited. When comparing these different exporter structures the different separation 
distances between the two NBDs are eye-catching. In the two structures of the E. coli and V. cholerae 
MsbA, the NBDs are separated by 61.69 – 68.46 Å (depending on the homodimer in the asymmetric 
unit) and 32.75 Å, respectively (distances are measured between Cα- positions of residues in the 
coupling helices, Figure 9 and Table 3). The NBDs of the Vibrio protein show an additional rotation of 
one domain with respect to the other(20). These observed separations of the NBDs in MsbA raised 
criticism regarding the physiological relevance of such conformations, in particular because the 
separated NBDs were involved in crystal contacts. However, by using electron spin resonance 
measurements (EPR) these conformations could be confirmed in solution(21, 22). In addition, two 
recently published P-gp structures support this conformational flexibility. In the mouse apo P-gp 
structure the NBDs are 34.77 – 35.90 Å (depending on the chain in the asymmetric unit) away from 
each other. In the C. elegans P-gp structure the motor domains are separated by 46.14 Å. In the 
ABCB10 structures the NBDs are separated by 29.83 Å, 28.84 Å and 25.1 Å, respectively. All three 
ABCB10 structures have two nucleotides bound at the NBD-NBD interface. The NBDs of TM287/288 
with one AMP-PNP molecule bound are only 29.13 Å apart and are interacting with each other via an 
extensive H-bonding network between the D-loop of NBD288 and the Walker A and switch motif of 
NBD287 (Figure 7). Basically the same distance can be observed in TM287/288 crystallized without 
nucleotide (28.89 Å), although the hydrogen bonding network at the degenerate site appears to be 
weaker than in the AMP-PNP structure (discussed above). Our analysis suggests that at least in 
(bacterial) heterodimeric ABC exporters the NBDs do not have to separate completely to exchange a 
nucleotide and remain in constant contact during cycling. 
4.3.6 Rigid body movements of the subdomains in the nucleotide binding 
domain 
Nucleotide binding domains can be divided into two individual subdomains. The larger of these two 
domains, the RecA-like domain, has a α/β-fold, whereas the smaller α-helical domain contains only 
alpha helices. The RecA-like domain bears the highly conserved Walker A and Walker B motifs 
common to all ATPases and the α-helical domain contains the ABC transporter specific ABC signature 
motif. By comparing isolated NBDs crystallized with and without nucleotides, rigid body rotations 
between RecA-like and α-helical domains were associated with nucleotide binding. In the full-length 
transporter context of TM287/288, we for the first time can analyze the structural consequences of 
nucleotide binding in an ABC exporter. In contrast to isolated NBDs, where rigid body movements up 
to 30 ° were observed between the RecA-like and the α-helical domain(23, 24), we observed only very 
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minor tilts of 2 ° upon binding of AMP-PNP to NBD287. Although information on eventual rigid body 
movements in NBD288 upon binding of the second nucleotide to the consensus site is missing, it is 
likely that interactions at the NBDs with the coupling helices, which interact with both the RecA-like 
and the α-helical domain as well as the intimate interdomain communication between the NBDs play a 
more important role than nucleotide binding with regard to rigid body rotations.  
The tilting angles between the RecA-like and the α-helical subdomain for two ABC importers for which 
crystal structures with and without bound nucleotides exist were calculated in addition, namely for the 
maltose transporter MalFGK and the vitamin B12 transporter BtuCD. The calculated angles for 
MalFGK(12, 13), which is a type I ABC transporter, were between 12 and 15 °. The analysis for the 
type II importer BtuCD(14-17), gave rotation angles between 2 and 3 °, which is as low as in 
TM287/288. Table 2 summarizes the segments used for the superimposition analysis and lists the 
angles calculated for the rotation of the α-helical subdomain. 
4.4 Discussion 
Although progress in the field of membrane protein crystallography is impressive, the amount of 
structural data of these flexible and relatively instable proteins remains scarce. In addition, often only 
unrelated proteins within a protein superfamily can be crystallized in different conformational states. 
Therefore, conclusions regarding the transport mechanism of a class of transporters are often based 
on rather speculative assumptions or inaccurate homology models. To overcome these limitations, 
obtaining crystal structures of one single protein in different conformations or in ligand-bound and 
ligand-free states at high resolution is highly desirable to draw meaningful conclusions regarding the 
function and mechanism of transporters under study.  
Here we present the apo structure of the heterodimeric ABC transporter TM287/288. Together with the 
recently published AMP-PNP structure of TM287/288, for the first time the consequences of nucleotide 
binding in one and the same full-length ABC exporter can be analysed. We observed that in the 
subclass of (bacterial) heterodimeric ABC exporters a full separation of the nucleotide binding 
domains, as seen for E. coli MsbA or P-gp, does not seem to be essential for nucleotide exchange and 
that the NBDs appear to be held constantly together by an extensive hydrogen bonding network at the 
degenerate ATPase site even in the absence of nucleotides. In addition, the often described rigid-body 
rotation in isolated NBDs between the alpha helical subdomain with respect to the RecA-like 
subdomain associated with nucleotide binding could not be observed. Most interestingly, we were able 
to gain insight into the mechanism of interdomain communication between the two ATPase sites 
promoted via the D-loops. The presence of a nucleotide bound to the degenerate site is sensed by 
residues of the Walker B motif and further transmitted in a long-range conformational change to the D-
loop to form two hydrogen bonds between the D-loop Asp501 of NBD287 and Thr390 of the Walker A 
motif of NBD288. These two H-bonds are disrupted when the nucleotide at the degenerate site 
dissociates (apo structure). In addition, nucleotide binding to the degenerate site breaks a hydrogen 
bond between the D-loop Asp523 and the ABC signature Ser493 of NBD288.  
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This new structure together with the recently solved AMP-PNP structure helps to better understand the 
mechanism underlying this medically relevant ABC exporter subtype, with eukaryotic representatives 
like CFTR, SUR1, Tap1/2 or MRP1. 
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TABLE 1 | DATA COLLECTION AND REFINEMENT STATISTICS 
 
Apo structureb) Apo structurec) AMP-PNP structure 
Data Collection 
   
Space group C2 C2 C2 
Cell dimensions    
a, b, c (Å) 214.64 
84.01 
114.11 
214.64 
84.01 
114.11 
216.33 
84.31 
115.78 
α, β, γ (º)  90.000 
93.268 
90.000 
90.000 
93.268 
90.000 
90.000 
91.923 
90.000 
Resolutiona) (Å) 2.60 (2.67-2.60) 2.53 (2.59-2.53) 2.6 (2.67-2.60) 
Rmerge (%) 5.3 (109.8) 5.3 (67.9) 6.2 (205.0) 
I/σI 23.15 (1.32) 23.81 (1.66) 17.65 (1.36) 
Completeness (%) 93.1 (64.6) 87.3 (25.6) 99.5 (99.4) 
Redundancy 3.8 (2.5) 3.8 (2.0) 6.8 (7.0) 
    
Refinement 
   
Resolution (Å)  30-2.53 25-2.6 
No. reflections (work/test)  59481/3003 63492/3181 
Rwork/ Rfree  23.85/29.06 22.68/27.06 
No. atoms    
    Protein  9126 9134 
    AMP-PNP  - 31 
    Mg2+  - 1 
   Water  12 - 
B-factors    
    Protein  109 123 
    Ligand  - 112 
    Ion  - 112 
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    Water  67 - 
R.m.s deviations    
    Bond lengths (Å)   0.004 0.004 
    Bond angles (º)  0.856 0.862 
a) Highest resolution shell is shown in parenthesis. 
b)
 Conventionally scaled data using XSCALE. 
c) Ellipsoidal truncation and anisotropy scaling was performed using the UCLA MBI Diffraction 
Anisotropy server(11).
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TABLE 2 | CALCULATIONS OF RIGID BODY ROTATION IN FULL-LENGTH ABC 
TRANSPORTERS 
 
  
Type I importer
----------------- Rec A-like domain ----------------- ----------------- Helical  domain ----------------- Rigid body rotation
fixed moving Segment 1 Segment 2 Segment 3 Segment 4 Segment 1 Segment 2 Segment 3 Segment 4 angle [°]
MalFGK 2R6G_Chain A 3PV0_Chain A 29-43 154-158 186-190 204-207 88-97 107-118 121-125 135-149 12.633
2R6G_Chain A 3PV0_Chain B 29-43 154-158 186-190 204-207 88-97 107-118 121-125 135-149 13.113
2R6G_Chain B 3PV0_Chain A 29-43 154-158 186-190 204-207 88-97 107-118 121-125 135-149 14.441
2R6G_Chain B 3PV0_Chain B 29-43 154-158 186-190 204-207 88-97 107-118 121-125 135-149 14.914
Type II importer
----------------- Rec A-like domain ----------------- ----------------- Helical  domain ----------------- Rigid body rotation
fixed moving Segment 1 Segment 2 Segment 3 Segment 4 Segment 1 Segment 2 Segment 3 Segment 4 angle [°]
BtuCD 4FI3_Chain C 1L7V_Chain C 26-40 154-158 185-189 204-207 88-97 105-114 120-122 126-143 2.556
4FI3_Chain C 1L7V_Chain D 26-40 154-158 185-189 204-207 88-97 105-114 120-122 126-143 2.556
4FI3_Chain D 1L7V_Chain C 26-40 154-158 185-189 204-207 88-97 105-114 120-122 126-143 2.484
4FI3_Chain D 1L7V_Chain D 26-40 154-158 185-189 204-207 88-97 105-114 120-122 126-143 2.478
4FI3_Chain C 2QI9_Chain C 26-40 154-158 185-189 204-207 88-97 105-114 120-122 126-143 2.882
4FI3_Chain C 2QI9_Chain D 26-40 154-158 185-189 204-207 88-97 105-114 120-122 126-143 2.871
4FI3_Chain D 2QI9_Chain C 26-40 154-158 185-189 204-207 88-97 105-114 120-122 126-143 2.795
4FI3_Chain D 2QI9_Chain D 26-40 154-158 185-189 204-207 88-97 105-114 120-122 126-143 2.79
4FI3_Chain C 4DBL_Chain C 26-40 154-158 185-189 204-207 88-97 105-114 120-122 126-143 2.955
4FI3_Chain C 4DBL_Chain D 26-40 154-158 185-189 204-207 88-97 105-114 120-122 126-143 2.933
4FI3_Chain C 4DBL_Chain H 26-40 154-158 185-189 204-207 88-97 105-114 120-122 126-143 2.95
4FI3_Chain C 4DBL_Chain I 26-40 154-158 185-189 204-207 88-97 105-114 120-122 126-143 2.933
4FI3_Chain D 4DBL_Chain C 26-40 154-158 185-189 204-207 88-97 105-114 120-122 126-143 2.877
4FI3_Chain D 4DBL_Chain D 26-40 154-158 185-189 204-207 88-97 105-114 120-122 126-143 2.854
4FI3_Chain D 4DBL_Chain H 26-40 154-158 185-189 204-207 88-97 105-114 120-122 126-143 2.871
4FI3_Chain D 4DBL_Chain I 26-40 154-158 185-189 204-207 88-97 105-114 120-122 126-143 2.854
Exporter
----------------- Rec A-like domain ----------------- ----------------- Helical  domain ----------------- Rigid body rotation
fixed moving Segment 1 Segment 2 Segment 3 Segment 4 Segment 1 Segment 2 Segment 3 Segment 4 angle [°]
TM287/288 …._Chain A …._Chain A 359-373 490-494 520-524 538-541 421-430 437-446 459-461 469-486 2.105
 83  
 Interdomain communication  
TABLE 3 | NBD SEPARATION IN INWARD-FACING ABC EXPORTERS 
Protein (PDB, Chain) Nucleotide(s)/Metal(s) Residue 1 Residue 1 Distance (Å) 
EcMsbA (3B5W, Chains A + B) — G213 G213 67.57 
EcMsbA (3B5W, Chains C + D) — G213 G213 68.46 
EcMsbA (3B5W, Chains E + F) — G213 G213 61.69 
EcMsbA (3B5W, Chains G + H) — G213 G213 62.19 
     
VcMsbA (3B5X, Chains A + B) — G213 G213 32.75 
     
TM287/288 (…., Chains A + B) AMP-PNP/Mg2+ G201 (TM287) G225 (TM288) 29.13 
TM287/288 (…., Chains A + B) — G201 (TM287) G225 (TM288) 28.89 
     
Pgp (3G5U, Chain A) — A256 F900 34.77 
Pgp (3G5U, Chain B) — A256 F900 35.90 
     
Pgp (4F4C) — S284 N944 46.14 
     
ABCB10 (4AYT) 2 AMP-PCP/2 Mg2+ N360 N360 25.10 
ABCB10 (4AYW) 2 AMP-PNP N360 N360 28.84 
ABCB10 (4AYX) 2 AMP-PCP/2 Mg2+ N360 N360 29.83 
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5.1 Abstract 
ATP binding cassette transporters shuttle various compounds across the lipid bilayer. The transport is 
energized by ATP binding and hydrolysis at two cytosolic ATPase sites. Numerous heterodimeric ABC 
exporters are characterized by the presence of functionally non-equivalent catalytic sites. Recently, 
the first full-length structure of the heterodimeric ABC exporter TM287/288 was determined [1]. 
Although the protein was captured in an inward-facing conformation, the nucleotide binding domains 
(NBDs) remained in a partial contact. Here we report a detailed description of the behavior of the 
isolated TM287/288 NBDs in solution. In addition we solved crystal structures of the individual NBDs 
and analyzed structural differences between the domains in isolation and in the context of the full-
length transporter. Our findings highlight the importance of conformational flexibility for the function of 
the NBDs.  
5.2 Introduction  
ATP binding cassette (ABC) transporters constitute one of the largest protein families and are 
abundantly represented in all kingdoms of life. These multi-domain integral membrane proteins utilize 
the energy of ATP hydrolysis to drive translocation of various compounds across cellular membranes. 
ABC transporters are crucial for diverse physiological processes such as the uptake of nutrients, 
homeostasis maintenance, resistance to toxins or antigen processing [2]. When impaired, the ABC 
transporters can cause hereditary diseases in humans, including cystic fibrosis [3], Stargardt disease 
[4] or adrenoleukodystrophy [5]. In addition, the ABC transporters are notorious for causing multidrug 
resistance of bacteria and tumor cells resulting in a chemotherapy failure.  
5.2.1 NBDs and their functional asymmetry 
All ABC transporters share a canonical architecture comprising two transmembrane domains (TMDs) 
and two cytosolic nucleotide binding domains (NBDs). While transmembrane domains of the ABC 
transporters differ significantly, the NBDs show a high degree of similarity. A number of monomeric [6-
10] and homodimeric [11-14] NBD structures were determined, providing valuable insights into the 
general fold, mode of the nucleotide binding and the functional dimeric arrangement, which were 
subsequently validated by structures of the full-length transporters [15-17]. The NBD encompasses 
several conserved motifs involved in nucleotide binding and hydrolysis, such as a Walker A motif that 
interacts with the α- and β-phosphates of nucleotides, a Walker B that contains a catalytic glutamate, 
an H-loop (or a switch region) with a conserved histidine and an ABC signature motif that contacts the 
γ-phosphate of the ATP. The functional NBD dimer contains two composite ATPase sites with both 
NBDs contributing to each of them. The Walker A, Walker B and the H-loop of one NBD are 
complemented with the signature motif of the second NBD so that nucleotides become sandwiched 
between the two NBDs [11, 18, 19]. Many of the heterodimeric ABC exporters, including the medically 
relevant examples TAP1/2, CFTR or SUR1 exhibit an intriguing asymmetry in the NBDs. These 
transporters contain substitutions in the conserved ATPase motifs. Typically NBD1 has an aspartate in 
place of a conserved glutamate in the Walker B and the histidine of the H-loop is substituted with a 
glutamine. The NBD2 has a non-canonical signature motif. Upon the NBD heterodimerization, the 
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divergent motifs align to form a non-canonical ATPase site, while the other site consists of consensus 
motifs. The consensus site has been demonstrated to be largely or solely responsible for the 
necessary ATPase activity and for the NBD closure [13]. In contrast, the non-canonical site is 
suggested to be catalytically incompetent. To date the reasons for this functional asymmetry remain 
unclear. A hypothesis of functional non-equivalence of the ATPase sites in ABC transporters has 
emerged from biochemical [20, 21] as well as from structural studies [22, 23]. In a recent study of 
Mittal et al. [24] the homodimeric ABC exporter MsbA was trapped in an asymmetric state using 
conformation-sensitive DARPin binders.  
5.2.2 The TM287/288 structure 
Recently, the first high resolution full-length structure of a heterodimeric ABC exporter, TM287/288 
was determined [1]. The transporter was captured in its inward-facing conformation. The structure 
revealed that the NBDs are only partially disegaged. So far all ABC exporters crystallized in an inward-
facing conformation were homodimeric and showed a complete separation of the NBDs with varying 
distances between them [17, 25, 26]. Although, the presence of the conformation with distantly spaced 
NBDs in solution was additionally confirmed by spectroscopic methods [27, 28], some studies argue 
whether the large NBD separation is necessary for drug binding and ATP hydrolysis [29]. It is also 
plausible that the heterodimeric ABC exporters undergo different conformational changes than the 
homodimeric counterparts and that a partial NBD opening (as opposed to complete separation) might 
be common to all heterodimeric exporters, however this hypothesis needs to be supported by 
additional studies. 
To date, the attempts to stabilize the TM287/288 in an outward-facing conformation for structure 
determination were not successful and assumptions made by comparisons with the outward-facing 
models of homodimeric exporters may be misleading. To gain more insight into the structural basis of 
the functional asymmetry in the heterodimeric ABC exporters we perfomed detailed functional and 
structural studies of both consensus and non-consensus NBDs of TM287/288 in isolation.  
5.3 Results and Discussion 
5.3.1 Protein purification and biochemical characterization 
The nucleotide binding domains of the heterodimeric ABC exporter TM287/288 are termed NBD287 
and NBD288 for NBD1 and NBD2, respectively. The NBD287 (residues 330-577) was expressed in E. 
coli, fused at the N-terminus to the His-tagged SUMO3 tag protein. After Ni-chelating chromatography 
purification, the SUMO3 tag was cleaved off using SUMO protease and the NBD287 devoid of tags 
was used for crystallization. The NBD288 (residues 353-592) was expressed with a C-terminal avi-tag 
followed by a His-tagged GFP. The GFP tag was cleaved off using 3C protease, leaving the avi-tag at 
the C-terminus of the domain. Despite the presence of the avi-tag, the domain migrated as a 
monodisperse species in size exclusion chromatography.  
Analytical size exclusion chromatography and analytical ultracentrifugation analyses showed that both 
domains are monomeric in solution and no ATP-induced dimerization could be observed (Figure 1). 
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The avi-tag does not affect the oligomeric state of NBD288, as the same migration behavior was also 
observed for a NBD288 construct devoid of tags (not shown). The domains alone or mixed have no 
detectable affinity for ATP and show no ATPase activity (data not shown), while under similar 
conditions the full-length transporter binds and hydrolyzes ATP [1]. 
5.3.2 Structural analysis 
NBD287 was crystallized at 1.95 Å resolution and solved by molecular replacement using NBD1 from 
the TM287/288 structure (PDB code 3QF4) as a search model. The final model was refined to 23.7 % 
(Rfree=25.76 %) and includes the residues 353-366, 409-569. The NBD288 crystals diffracted to 2.3 Å. 
The structure was solved by molecular replacement using NBD2 of the TM287/288 structure as a 
search model (PDB code 3QF4) and refined to 19.13 % (Rfree=23.89 %). The final model 
encompasses residues 353-519 and 523-592 of the domain. In addition, the model contains an N-
terminal serine (cloning artifact) and 17 residues of the C-terminal avi-tag. The data collection and 
refinement details are summarized in Table 1.  
5.3.3 Domain architecture 
The fold of the ATP binding cassette has been established by numerous previously reported structures 
of isolated NBDs (over 50 NBD structures are listed in [9]) and full-length ABC transporters [15-17, 25, 
26, 30-36]. The NBD fold consists of a catalytic and a helical domain. The catalytic domain can be 
further subdivided into two subdomains: the RecA-like (or F1) [37] and an ABC-specific β [38]. The 
catalytic domain, common to all P-loop ATPases, contains 2 β-sheets flanked by helices and harbors 
the conserved motives which form a nucleotide binding site: the Walker A, the Walker B, the switch (H-
loop), the D-loop and the A-loop. The helical domain is a bundle of four α-helices typical for ABC 
transporters and contains the ABC signature motif. The topology scheme with the boundaries of the 
secondary structure elements and the location of the conserved elements is shown in Figure 2.   
The NBD287 structure 
Our model of the NBD287 encompasses the helical domain and most of the RecA-like subdomain but 
lacks the ABC-β subdomain, the loop-helix motif containing the Walker A and eight C-terminal 
residues. The absence of the electron density, despite the high diffraction quality, suggests that the 
missing portion of the domain is inherently flexible. The other functionally relevant motifs including the 
non-canonical ABC signature, Walker B, D-loop and the switch motives are well ordered. Interestingly, 
the very same structures were independently obtained from three different protein constructs: NBD287 
with the N-terminal avi-tag (pBXNAC3GH_NBD287), NBD287 expressed with the cleavable N-terminal 
SUMO protein tag (pET11M-SUMO-FX-NBD287) and NBD287 with the cleavable N-terminal 10xHis-
tag (pBXNH3_NBD287). Mass spectrometry analysis of the dissolved crystals did not reveal protein 
fragmentation that would correspond to the portion seen in the structure (data not shown). 
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5.3.4 Comparison with the corresponding domain of the full-length TM287/288 
transporter  
The full-length TM287/288 exporter was crystallized in the nucleotide-bound [1] and nucleotide-free 
(Hohl et al., in preparation) states. In both cases the transporter is trapped in an inward-facing 
conformation with the NBDs in a partially disengaged arrangement. In contrast to other inward-facing 
ABC transporter structures, where the NBDs are fully separated, in the case of TM287/288 the NBDs 
remain sealed together at the degenerate ATPase site, irrespectively of whether it is nucleotide-bound 
or nucleotide-free. The availability of the NBD structures from the same system in isolation and in the 
full-length context provides the unique opportunity to describe the structural plasticity of the NBDs. In 
the context of the full-length transporter, the NBDs form extensive inter- and intrachain interactions. 
Isolated domain structures allow for a better interpretation of the extent of conformational adjustments 
necessary to form a functional molecular complex. And this, in turn, gives valuable insight into the 
mechanistic features of the ATP hydrolysis and transport.  
Superimposition of the structured part of the NBD287 in isolation with its counterpart NBD1 of the full-
length TM287/288 structures results in an RMSD of about 1 Å (backbone carbon alignment with 
nucleotide-bound NBD1 along 158 atoms, with nucleotide-free NBD1 along 155 atoms) (Figure 3a and 
3b). The secondary structure element matching (SSM) results in a slightly higher RMSD of around 1.4 
Å over 168 residues. When secondary structure elements of the catalytic domain are used for 
superimposition, the relative rotation of the helical domain becomes apparent. In the isolated domain, 
the bundle of helices rotates away from the core beta sheet by 10 degrees relative to the nucleotide-
bound and 11 degrees relative to the nucleotide-free structure (Figure 3c and 3d). This high degree of 
flexibility of the helical domain in NBDs has been described before [7, 9, 38-40]. The flexibility of this 
region is not unanticipated as it is extensively involved in interchain interactions in the intact protein. In 
the full-length transporter the helical domain accommodates the intracellular loops extending from the 
transmembrane portion of the transporter and its signature motif complements the composite ATPase 
site in the dimerized NBD state. We also compared the relative positions of the conserved motives of 
our structure in relation to the full-length protein (Figure 4). Unexpectedly, the arrangement of the 
Walker B, H-loop and the D-loop resembles the nucleotide-bound NBD1 of the intact TM transporter. 
The hydrogen bond network of the aspartate 495 (corresponding to the canonical general base 
glutamate) in the isolated domain is slightly altered with respect to the nucleotide-bound intact 
transporter. Here the aspartate 495 points towards the H-loop and makes a hydrogen bond with the 
glutamine 526 that substitutes the canonical histidine of the catalytic dyad (Figure 5a). In the full-length 
structure with the AMP-PNP bound, the aspartate 495 was locked in a hydrogen bond network with 
serine 498 of the D-loop (Figure 5b). In both structures the Q-loop is beyond the hydrogen bonding 
distance to aspartate 495. The situation in the nucleotide-free full-length structure is significantly 
different, as the aspartate 495 is withdrawn from the interaction with the H-loop but it interacts 
extensively with the remodeled D-loop via hydrogen bonds with serines 498 and 499. It is also close 
enough to the Q-loop to form a hydrogen bond with the conserved glutamine 414 (Figure 5c). In 
summary, the positioning of the Walker B, the H-loop and of the D-loop is similar to the nucleotide-
bound NBD1 of the full-length TM287/288 structure. Incapability of the isolated NBD287 to bind ATP 
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might result from the flexibility of domain portion that harbors the Walker A motif and that was not 
structured in our model.  
The ABCβ-subdomain of the isolated NBD287 is flexible when taken out of the context of the 
full-length transporter 
In the full-length TM287/288 structure, the ABCβ-subdomain of NBD287 forms one side of the binding 
groove for the intracellular loop 4 (ICL4) that protrudes from the TM288 polypeptide. The ICL4 
contains a coupling helix – a conserved element that stabilizes interchain and interdomain interactions.  
Several residues of the coupling helix make direct contacts with the ABCβ-subdomain stabilizing its 
position (Figure 6). Furthermore, the Walker A motif, that directly precedes the ABCβ region, is 
interacting with the D-loop and D-loop helix (a helix that immediately follows the D-loop) of the 
neighboring NBD288 contributing to the composite ATPase site. Therefore, it is likely that in the 
absence of the TM288 (its NBD and coupling helix) the conformational freedom of the ABCβ 
subdomain and of the loop that harbors the WalkerA motif is increased. This would explain the lack of 
electron density corresponding to this part of the NBD287.  
The NBD288 structure 
Current structural knowledge of the NBD2 is very limited. Apart from full-length TM287/288, the only 
NBD2 structure deposited comes from the multidrug resistance protein 2 of Plasmodium yoelli (PDB 
code 2GHI) published by a Structural Genomics Consortium [41]. Our model covers the whole domain 
with the exception of three residues corresponding to the D-loop. The overall structure is similar to the 
one observed in the intact transporter. When compared with the nucleotide-bound full-length structure, 
the superimposition of the Cα atoms results in a RMSD of 1.3 Å (over 215 atoms) and secondary 
structure matching – in a RMSD of 1.5 Å (Figure 7a). Comparison with the nucleotide-free TM287/288 
structure results in an even closer match of a RMSD = 1.28 Å over 220 Cα atoms and a RMSD of 1.45 
Å for secondary structure matching. The relative position of the catalytic and helical domain is quite 
different from the one seen in the domains of the intact transporter. When the models are 
superimposed using secondary structure elements of the catalytic domain, the relative displacement of 
the helical domain is emphasized (Figure 7b). Similarly as seen in the NBD287, the helical domain 
rotates outwards from the RecA core by 11 and 10 degrees when compared to the nucleotide-bound 
and the nucleotide-free TM287/288 structures, respectively. Interestingly, we observe a significant 
displacement of the D-loop helix which tilts along its long axis away from the RecA β-sheet by 12 and 
11 degrees with respect to its position in the nucleotide-bound and nucleotide-free intact transporter 
structure, respectively (Figure 7c). This rotation seems to be of functional importance as the position of 
this helix is sensitive to the conformation of the D-loop and contacts the Walker A of the neighboring 
NBD, and therefore is important for coordination of the events taking place in the two ATPase sites. 
The full-length TM287/288 structures, our isolated NBD288 and the MRP2 NBD2 structures were 
crystallized devoid of nucleotides. However, the generally accepted hypothesis is that NBD2 is 
predominantly responsible for ATP hydrolysis in heterodimeric ABC exporters. In the context of the 
full-length protein (irrespectively of whether a nucleotide in the degenerate site is bound or not) the 
catalytic base (glutamate 517) following the Walker B motif adopts a very unusual position, pointing its 
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side chain away from the active site (Figure 9b). In the NBD288 structure, the active site is rearranged 
when compared to the intact transporter structure. The catalytic glutamate is flipped and points more 
towards the active site but still is locked in a state incompetent for catalysis. It interacts with the 
backbone amide of the histidine 548 and with the following residues of the H-loop. The interactions 
with the residues following the H-loop distort the alpha helical geometry of the 551-556 helix, which in 
our structure adopts a 310 geometry (Figure 9a). The glutamate  ̶  H-loop backbone interaction has 
been seen before in the structure of the isolated HlyB-NBD where the histidine was substituted by an 
alanine [12]. Such positioning of the catalytic base does not allow polarization of the attacking water 
necessary for catalysis. The thorough structural analysis of the maltose transporter in different states 
of catalysis showed that in the presence of the nucleotide the catalytic base is expected to interact 
with the imidazole ring of the H-loop histidine that orients it toward the γ-phosphate of the ATP where it 
is in a suitable distance to deprotonate the attacking water molecule [30]. The same is true for the 
ABC exporter Sav1866 [42]. The active site of the AMP-PNP bound Sav1866 is shown in Figure 9c.  
The C-terminal avi-tag of NBD288 mediates crystal contacts 
Inspection of the NBD288 crystal packing revealed an intriguing feature of the crystal lattice. The 
NBD288 molecules are arranged as beads along the filament formed by protruding C-terminal avi-tags 
(Figure 10). The avi-tag peptides specifically interact forming extended antiparallel beta sheets that fit 
in the unoccupied ATP-binding groove of the symmetry related NBD288 molecule. The filaments are 
spatially separated resulting in a high solvent content of the asymmetric unit of >63 %.  
The interfacial areas of the degenerate ATPase site are inherently more flexible 
The electron density maps for both the NBD287 and the NBD288 allow fitting of only parts of the 
sequence of the domains. This means that certain areas of the NBDs must be flexible. When the 
partial structural models of NBD287 and NBD288 are oriented as they would face each other in the 
full-length protein, we see a striking correlation of the disordered areas with the location of the 
degenerate ATPase site. The parts that are missing in our models (the Walker A and the ABC-specific 
β subdomain of NBD1 and the D-loop of the NBD2) are parts of the composite interface in the intact 
transporter (Figure 11). In addition, an analysis of the temperature factor distribution along the isolated 
NBDs suggests that this area is relatively more fexible than the region harboring the consensus site  
(Figure 11b). Previous studies on the CFTR showed that during the functional cycle, the degenerate 
site most likely stays connected for most of the time and only the second ATPase site (consensus site) 
undergoes partial opening allowing for nucleotide exchange [43]. Analysis of the full-length TM287/288 
transporter structure supports the hypothesis of only partial disengagement of the NBDs during the 
catalytic cycle. Our structural analysis emphasizes higher flexibility/stability of this area and suggests 
that upon disengagement, the separated halves of the degenerate site are highly flexible. 
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5.4 Conclusions 
The comparison of the structures of the intact transporter with the isolated NBDs of the same protein 
provides an unprecedented insight into the mechanism and mechanics involved in ATPase hydrolysis 
and transport. In addition, to our best knowledge, this is the first report in which both NBD structures of 
a heterodimeric transporter are described.  
The isolated NBDs of TM287/288 are unable to hydrolyze ATP and they do not dimerize. This clearly 
suggests that a productive dimerization can only take place in the full-length protein. It has been 
proposed that a nucleotide acts as molecular glue keeping the degenerate site together. However, this 
seems unlikely since the TM287/288 structure without nucleotide (Hohl et al., Chapter 4) shows the 
same NBD arrangement with the NBDs in contact at the degenerate site.  
The isolated NBD structures revealed that the domains exhibit remarkable plasticity that is necessary 
to support inter- and intrachain interactions in the full-length structure and conformational changes 
during the catalytic cycle. The helical subdomains of both NBDs possess certain autonomy that is 
necessary to accommodate the intracellular loops protruding from the transmembrane portion and 
containing the coupling helices. The stability of the ABCβ subdomain in NBD287 is compromised in 
the absence of TM288. In the full-length structure the ABCβ subdomain is supported by the interaction 
with the TM288 coupling helix and with the D-loop of the NBD288. The interfacial areas that build the 
canonical ATPase site (Walker A, Walker B and H-loop of NBD288 and D-loop and ABC signature of 
NBD287) seem to be rather stable and the catalytic site remains preformed even outside the context 
of the full-length protein and in the absence of nucleotides. In contrast, the elements that build the 
degenerate ATPase site could not be resolved in the isolated structures. This suggests that this area 
is not preformed and only becomes structured in the heterodimeric arrangement of the intact 
transporter. Therefore our analysis emphasizes the structural asymmetry of the system by identifying 
the degenerate composite ATP-binding interface as a region of higher inherent flexibility. 
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5.5 Experimental Procedures 
5.5.1 Cloning of the TM287/288 NBDs 
The two NBDs of the heterodimeric ABC transporter TM287/288 were amplified from the FX-vector 
pBXNH3_TM287/288 [44] used for the structure determination of the full-length transporter [1]. For 
each NBD, ten SapI-restriction enzyme based FX-vectors were constructed for test expressions. 
Cloning was performed as described in [44]. The primers NBD287_for, NBD287_rev, NBD288_for and 
NBD288_rev (sequences see below) were used to amplify the two soluble domains, both starting with 
a conserved glycine residue (Gly330 (NBD1) and Gly353 (NBD2) of the full-length transporter). The 
inserts were cloned into the FX-expression vectors pBXNH3, pBXC3H [44] and pBXC3GH (Geertsma 
et al., unpublished). Additionally, both inserts were ligated into the FX-avi-tag vectors pBXNH3A, 
pBXNH3CA, pBXNAC3H, pBXNAC3GH, pBXCA3H and pBXCA3GH (Geertsma et al., unpublished). 
Table 2 illustrates the nomenclature used for the vector annotation. The six avi-constructs were both 
used for crystallization attempts as well as for immobilization- and selection purposes (Hohl et al., 
unpublished). The vector pETM11-SUMO3GFP [45] was used as the only pET-based vector for test 
expressions. For this purpose the vector was modified to make it available for FX-cloning, with the 
exception that this resulting vector does not contain a ccdB-cassette and therefore has to be 
predigested with SapI and separated from its insert via agarose gel. An undesirable SapI site on 
pETM11-SUMO3GFP was removed by QuickChange mutagenesis using the primers 
pET11M_SUMO_delSapI_for and pET11M_SUMO_delSapI_rev (sequences see below). This SapI-
free pET11M-SUMO3GFP vector was then cleaved with the restriction enzymes AgeI and HindIII and 
ligated with the two annealed oligonucleotides pETM11_FX_for and pETM11_FX_rev (sequences see 
below). pETM11_FX_for together with pETM11_FX_rev form overhangs compatible with AgeI and 
HindIII. This resulted in the SapI-based pET11M-SUMO-FX expression vector. 
NBD287_for: 5’-ATATGCTCTTCTAGTGGGAGCGTTTCCTTCGAAAATGTC-3’ 
NBD287_rev: 5’-TATAGCTCTTCATGCGGCATCGTTCATCACCCCGTTTCC-3’ 
NBD288_for: 5’-ATATGCTCTTCTAGTGGAGAAATCGAGTTCAAGAATGTC-3’ 
NBD288_rev: 5’-TATAGCTCTTCATGCTGCTTCTTTTTCTACAACGAGACC-3’ 
pET11M_SUMO_delSapI_for: 5’-GAGGAAGCGGATGAGCGCCTG-3’ 
pET11M_SUMO_delSapI_rev: 5’-CAGGCGCTCATCCGCTTCCTC-3’ 
pETM11_FX_for: 5’-CCGGTGGAAGTAGAAGAGCATATGCTCTTCTGCATAATA-3’ 
pETM11_FX_rev: 5’-AGCTTATTATGCAGAAGAGCATATGCTCTTCTACTTCCA-3’ 
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5.5.2 Test expression of the NBD287 and NBD288 
E. coli MC1061 (for pBX vectors) and BL21 (DE3) cells (for pET vectors) transformed with the desired 
vectors were used to produce the NBDs in shaking flasks containing 100 ml LB media, 100 µg/ml 
ampicillin (pBX) or 50 µg/ml kanamycin (pET) at 30 °C. Protein production was induced with 0.0025 % 
L-arabinose (pBX) or with 0.5 mM IPTG (pET) at an OD600 = 1 for about four hours. The cells were 
then spun down at 5000 x g and frozen at -20 °C. After resuspension in 20 mM Tris-HCl pH 8.0, 200 
mM NaCl, 3 mM MgCl2 and the addition of DNase I the cells were treated by sonication. To get rid of 
unopened cells and cell fragments the suspension was centrifuged again for half an hour at 15’000 x 
g. The supernatant was subsequently loaded on a Ni-NTA column, washed with 50 mM imidazole pH 
7.5, 200 mM NaCl and 10 % glycerol. Elution from the column was performed with 200 mM imidazole 
pH 7.5, 200 mM NaCl and 10 % glycerol. Collected fractions were analyzed for expression yield via 
SDS-PAGE. The best expressing constructs were further analyzed by size exclusion chromatography 
for their monodispersity. The best behaving constructs are further described in the part expression, 
purification and crystallization and an additional rating is given in Table 3. 
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5.5.3 Protein expression and purification 
The NBD287 structure was determined for the protein expressed from pET11M-SUMO-FX_NBD287 
construct. For overexpression freshly transformed BL21 E. coli cells were cultured in LB medium at 37 
°C in the presence of kanamycin (50 µg/mL) until optical density (OD600) reached 0.8. The culture was 
then induced by IPTG (0.1 mM final) and the expression was carried out for 4 hours at 30 °C. For the 
cell lysis, the pellet was resuspended in a lysis buffer (20 mM Tris-HCl pH 8.0, 200 mM NaCl, 10 mM 
imidazole, 2 mM MgCl2, EDTA-free protease inhibitor cocktail (Roche), 1 mM PMSF, 10 µg/mL 
DNaseI). Upon disruption, the lysate was cleared by centrifugation for 30 min at 20’000 rpm at 4 °C 
and applied onto a gravity flow Ni-NTA column equilibrated with 20 mM Tris-HCl pH 8.0, 200 mM 
NaCl, 10 mM imidazole, 10% glycerol. Unbound proteins were washed by applying a buffer containing 
40 mM imidazole. The SUMO3-NBD287 fusion was eluted in buffer containing 200 mM imidazole. For 
buffer exchange, the protein was applied onto a PD-10 desalting column (GE Healthcare) prior to an 
overnight proteolytic cleavage of the SUMO3-tag using the SenP2 protease (at 1:500 of the 
SenP2:SUMO3-fusion w/w ratio). The SUMO and the SenP2 were re-bound to the nickel resin. 
Directly before crystallization of NBD287, devoid of tags, it was subjected to size exclusion 
chromatography on a Superdex 75 column (10/300 GL, GE Healthcare) with 20 mM Tris-HCl pH 7.5, 
150 mM NaCl as a running buffer, and concentrated to around 12 mg/mL (MWCO=10 kDa). 
The NBD288 expression construct spans positions 353-598 of the TM0288 polypeptide followed by an 
avi-tag, 3C cleavage site, GFP and 10-His tag. For protein overexpression, freshly transformed 
MC1061 E. coli cells were grown in 2YT medium supplemented with ampicillin (100 µg/mL) to OD600 
between 0.9 to 1 and then induced by adding L-Arabinose (final concentration 0.0025% w/v). The 
expression was carried out for 5 hours at 30 °C. Harvested cells were disrupted in lysis buffer: 20 mM 
Tris-HCl pH 8.0, 200 mM NaCl, 5 mM MgCl2, EDTA-free protease inhibitor cocktail, 1 mM PMSF, 10 
µg/mL DNaseI. The lysate was cleared by centrifugation at 20’000rpm for 30 minutes at 4 °C and 
applied onto a gravity flow column with Ni-NTA resin equilibrated with 20 mM Tris-HCl pH 8.0, 200 mM 
NaCl. Unbound proteins were washed with a buffer containing 40 mM imidazole. The protein was 
eluted using buffer containing 200 mM imidazole. In order to remove imidazole, the protein was 
applied onto a PD-10 desalting column. The GFP-His tag was removed by an overnight enzymatic 
cleavage using a His-tagged 3C protease at a 1:20 ratio (w/w) enzyme to fusion protein.  The cleaved 
tags and the protease were re-bound to the Ni-NTA agarose and the NBD288-avi protein. Directly 
before crystallization the NBD288-avi was subjected to size exclusion chromatography on the 
Superdex 75 column (GE Healthcare) equilibrated with 20 mM Tris-HCl, 150 mM NaCl, pH 7.5 and 
concentrated to around 10 mg/mL (MWCO=10 kDa).  
5.5.4 Analytical size exclusion and ultracentrifugation 
Analytical size exclusion chromatography was performed on the HPLC system (Agilent 1200 series, 
Agilent Technologies) using a Superdex 200 column (5/150, GE Healthcare). For the runs without 
nucleotides the column was equilibrated with 20 mM Tris-HCl pH 7.5, 150 mM NaCl and samples were 
incubated with 1 mM EDTA in order to exclude potential effects caused by any contaminating 
magnesium. For the analysis in the presence of ATP, the column was equilibrated with at least three 
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column volumes of the same buffer with addition of 1 mM MgCl2 and 1 mM ATP and the protein 
samples were incubated with 1-5 mM MgATP prior to injections. The NBD mixture was prepared by 
mixing equimolar amounts of NBDs. In addition, we performed the separation runs in the absence of 
magnesium which did not reveal any different migration behavior of the domains (not shown).  
Sedimentation velocity analytical ultracentrifugation was performed using an Optima XL-1 centrifuge 
(Beckman Coulter) using epoxy counter pieces with sapphire windows. After size exclusion, the 
protein samples were diluted to an appropriate concentration to reach A280nm~0.7. The NBD mixture 
was prepared by mixing NBDs at equimolar concentration and addition of 1 mM MgCl2 and 1 mM ATP. 
The centrifugation was carried out at 4 °C and at 40’000 rpm. 300 absorption scans were collected 
and the data were analyzed using  the SedFit software [46]. 
5.5.5 Crystallization and structure determination 
NBD287 and NBD288 were subjected to vapour diffusion crystallization. Initial crystal screening was 
done with the use of a nanoliter drop robotic dispenser of the NCCR high-throughput crystallization 
facility. NBD287 crystallized at 20 °C in hanging drops. The protein was mixed at 1:1 ratio with 
reservoir solution containing 100 mM Tris pH 7.8, 100 mM sodium acetate, 25 % (w/v) PEG 2000 
MME. The crystals were transferred to the cryo solution containing 30 % PEG 2000 MME prior to cryo-
cooling in liquid nitrogen. Several conditions yielded crystals for the NBD288-avi construct and the 
final data was collected from a crystal grown at 20 °C in sitting drops containing a 1:1 mixture of 
protein and reservoir solution: 100 mM sodium acetate pH 5.5, 6 % (w/v) PEG 550 MME, 6 % (w/v) 
PEG 20’000, 200 mM MgCl2. The crystals were transferred into the cryo solution containing 25 % 
ethylene glycol and cryo-cooled in liquid nitrogen. Diffraction data were collected at beamline X06SA 
of the Swiss Light Source (SLS, Villigen, Switzerland) equipped with PILATUS detector (Dectris). Data 
were indexed with XDS [47] and scaled with XSCALE of the CCP4 package [48]. The free R factor 
(Rfree) was calculated from 5 % of randomly chosen reflections. The phases were obtained by 
molecular replacement in PHASER [49] using a model derived from the full-length TM287/288 
transporter structure (PDB code 3QF4). The structure was built into the electron density using COOT 
[50] and refined with PHENIX [51]. 
5.5.6 Mass spectrometry analysis of the dissolved NBD287 crystals 
The NBD287 crystals were extensively washed in the reservoir solution and dissolved in distilled 
water. The MALDI-MS analysis was performed at the Functional Genomics Center Zurich (FGCZ) of 
the University of Zurich and ETH Zurich.  
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Table 1. Data collection and refinement statistics. 
 NBD287 NBD288 
Data collection 
Beamline 
 
X06SA 
 
X06SA 
 
Space group P6522 P3221 
Cell dimensions 
a, b, c (Å) 
α, β, γ (°) 
 
80.15, 80.15, 129.55 
90, 90, 120 
 
58.3, 58.3, 208.69 
90, 90, 120 
Resolution (Å) 47.35 -1.95 49.07-2.3 
Rmeas (%) 4.7 (67.3) 9.3 (96.7) 
I/σI 30.19 (4.35) 19.94 (3.31) 
Completeness (%) 100 (100) 99.99 (100) 
    
 
Refinement 
 
  
Resolution (Å) 1.95 2.3 
Number of reflections 18606 19132 
Rwork/Rfree (%) 23.71/25.76 19.13/23.89 
No. of atoms 
     Protein 
     Solvent 
 
1376 
76 
 
2053 
139 
Average B-factors (Å2) 
    Protein 
    Solvent 
 
23.0 
19.9 
 
69.9 
70.1 
R.M.S. deviations 
    Bond lengths (Å) 
    Bond angles (°) 
 
0.008 
1.139 
 
0.009 
1.149 
Ramachandran plot (%) 
    Favoured 
    Allowed 
 
98.84 
1.16 
 
98.04 
1.96 
 
Values in parenthesis correspond to the highest resolution shell. 
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Table 2. The NBD construct annotation 
pBXNH3 10His-3C-NBD 
pBXC3H NBD-3C-10His 
pBXC3GH NBD-3C-GFP-10His 
pBXNH3A 10His-3C-AviTag-NBD 
pBXNH3CA 10His-3C-NBD-AviTag 
pBXNAC3H AviTag-NBD-3C-10His 
pBXNAC3GH AviTag-NBD-3C-GFP-10His 
pBXCA3H NBD-AviTag-3C-10His 
pBXCA3GH NBD-AviTag-3C-GFP-10His 
 
 
Table 3. Analysis of the expression yield and oligomeric behavior of the various NBD 
constructs. 
 
  
 105  
 Subdomain flexibility in the NBDs  
Figure 1  
 
 
Figure 1 Oligomeric behavior of the NBDs and their mixture 
(a) Analytical size exclusion chromatography of the NBDs in the absence of nucleotides. (b) Analytical 
size exclusion chromatography of the NBDs in the presence of MgATP. (c) Analytical 
ultracentrifugation of NBDs and their mixture in the presence of MgATP. 
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Figure 2  
 
 
Figure 2 Topology schemes of the NBDs indicating subdomain organization and position of the 
conserved elements.  
The Walker A is depicted in red, the Walker B - in orange, the ABC signature - in green, the Q-loop - in 
yellow. The dotted line indicates areas not resolved in the structures. (a) The NBD287 (b) The 
NBD288. 
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Figure 3  
 
 
Figure 3 The NBD287 structure in isolation and in the context of the full-length.  
Alignment of the Cα atoms of the isolated NBD287 with the NBD1 of nucleotide-bound TM287/288 (a), 
and with NBD1 of nucleotide-free TM287/288 (b). Rotation of the helical domain in the isolated 
NBD287 (slate blue) with respect to its position in NBD1 of nucleotide-bound TM287/288 (aquamarine) 
(c), and in NBD1 of nucleotide-free TM287/288 (light gray) (d). 
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Figure 4  
 
 
Figure 4 Location of the conserved motifs of the NBD287 in isolation and in the context of the 
full-length protein.  
The isolated NBD287 (slate blue) was superimposed on the NBD287 from the nucleotide-bound full-
length structure (aquamarine) (c) and on the NBD287 from the nucleotide-free full-length structure 
(light gray) (b). The conserved motifs were depicted as following: the Walker B - in orange, the Q-loop 
- in yellow, the D-loop - in black, the H-loop - in dark blue, the Walker A - in red. The tyrosine of the A-
loop and the noncanonical glutamine of the H-loop are depicted as sticks.  
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Figure 5  
 
 
 
Figure 5 Catalytic site of the NBD287. 
The catalytic site of: the isolated NBD287 (a), the nucleotide-bound NBD287 from the full-length 
TM287/288 structure (PDB code 3FQ4) and the nucleotide-free TM287/288 full-length structure (c). 
The conserved asparagine (Asp494) and non-canonical asparagine (Asp495) residues of the Walker B 
(orange) and residues within the hydrogen bonding distance to them are depicted as sticks. The 
residues which belong to the coserved motifs are colored according to the same coding as before. For 
orientation the protein context of the catalytic site is shown as cartoon and the conserved elements are 
colored as before. Additionally, in (b) the AMP-PNP molecule and magnesium ion are depicted as 
sticks and green sphere. Hydrogen bonds are depicted as black dashed lines.  
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Figure 6  
 
 
Figure 6 The ABCβ subdomain of NBD287 forms a binding groove for the coupling helix from 
TM288.  
Side (a) and top (c) view on the intracellular loop 4 (ICL4) (light pink) containing the coupling helix 
(green). The coupling helix lies in the binding groove created between the helical (blue dashed line) 
and ABCβ subdomains (gray dashed line) of the NBD287 in the full-length TM287/288 structure. Side 
(b) and top (d) view on the ICL4 superimposed on the incomplete isolated NBD287 structure. The 
NBD287 residues in a close proximity to the coupling helix (within 5 Å) are colored in yellow.  
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Figure 7  
 
 
Figure 7 The NBD288 structure in isolation and in the context of the full-length.  
The Cα atom alignment of the isolated NBD288 (purple) with the NBD2 of nucleotide-bound 
TM287/288 – light pink (a). Rotation of the helical domain in the isolated NBD288 (purple) with respect 
to its position in the NBD2 of the nucleotide-bound TM287/288 – light pink (b). The D-loop helix tilting 
in the isolated NBD288 structure (purple) in relation to its position in the NBD2 of nucleotide-bound 
TM287/288 – light pink (c). 
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Figure 8  
 
 
Figure 8 Location of the conserved motifs of the NBD288 in isolation and in the context of the 
full-length transporter.  
The isolated NBD288 (purple) was superimposed on the NBD288 from the nucleotide-bound full-
length structure (light pink) (c) and on the NBD288 from the nucleotide-free full-length structure (dark 
gray) (b). The conserved motifs were depicted as following: the Walker B - in orange, the Q-loop - in 
yellow, the D-loop - in black, the H-loop - in dark blue, the Walker A - in red. The tyrosine of the A-loop 
and the histidine of the H-loop are depicted as dark blue sticks.  
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Figure 9  
 
 
 
Figure 9 Catalytic site of the NBD2 
The catalytic site of: the isolated NBD288 (a), the NBD288 from the full-length TM287/288 protein 
(PDB code 3FQ4) and the nucleotide-bound Sav1866 full-length structure (PDB code: 2ONJ) (c). The 
conserved asparagine (Asp516 in TM287/288 and Asp502 in Sav1866) and glutamine (Glu517 in 
TM287/288 and Glu503 in Sav1866) residues of the Walker B (orange) and residues within the 
hydrogen bonding distance to them are depicted as sticks. The residues which belong to the coserved 
motifs are colored according to the same coding as before. The histidine of the H-loop (His548 in 
TM287/288 and His534 in Sav1866) is depicted in dark blue. The glutamine of the Q loop (Gln436 in 
TM287/288 and Gln422 in Sav1866) is depicted in yellow. Additionaly in (c) the AMP-PNP molecule is 
depicted as sticks. For orientation the protein context of the catalytic site is shown as cartoon and the 
conserved elements are colored as before. Hydrogen bonds are depicted as black dashed lines.  
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Figure 10 
 
 
Figure 10 C-terminal avi-tag of the NBD288 mediates crystal contacts 
(a) Fragment of the crystal lattice showing the filament-like organization of the NBD288 along the 
dimerized peptide linkers. Each symmetry-related NBD288 is depicted as cartoon in different color. 
The C-terminal tags are depicted as sticks and colored according to the color of the domain they come 
from. (b) cartoon representation of two C-terminal tags from symmetry-related NBD288s. (c) stick 
representation of two interacting C-terminal tags  with polar interactions depicted with dashed lines.  
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Figure 11  
 
 
Figure 11 Flexibility of the degenerate ATPase site.  
(a) The isolated NBDs were superimposed on the full-length TM287/288 structure using their helical 
sub-domains. The parts of the intact transporter corresponding to the missing elements of the isolated 
domains are depicted as surface. AMP-PNP molecule is depicted as red sticks. (b) The isolated 
domains in the worm-like representation are oriented as in (a) and colored according to the B factor. 
The worm thickness is proportional to the backbone B-factor. 
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